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ABSTRACT
Protection against atherosclerosis by a non-native pentameric CRP that shares its ligand
recognition functions with an evolutionarily distant CRP
by
Asmita Pathak

C-reactive protein (CRP) is an acute phase protein of the innate immune system that has been
evolutionarily conserved. Human CRP is known to exist in two different pentameric
conformations; native CRP and non-native CRP that possess differential ligand recognition
functions. The structure of CRP evolved from arthropods to humans, in terms of subunit
composition, disulfide bonds, and glycosylation pattern. Along with change in structure, the gene
expression pattern of CRP also evolved from a constitutive protein in lower invertebrates to an
acute phase protein in humans. The objective of this study was to determine the function of a
non-native pentameric CRP, that binds to atherogenic LDL, in atherosclerosis and compare the
ligand recognition functions of human pentameric CRP with an evolutionary distant CRP for
understanding the evolution of the structure of CRP. Additionally, in vitro reporter gene assays
were used to gain further insight into the regulation of human CRP gene expression by an IL-6
inducible transcription factor, STAT3. We observed that CRP, in its non-native pentameric
conformation, binds to atherogenic LDL and slows the progression of atherosclerosis in a sitespecific manner in high fat diet fed LDLR-/- mice. Further, we observed that the ligand
recognition function of CRP from an evolutionary conserved species, Limulus polyphemus, is
different than that of native pentameric human CRP, but overlaps that of non-native pentameric
human CRP. Lastly, we screened the proximal 300 bp region of the CRP promoter and identified
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a novel STAT3 binding site at position -134 located upstream of the previously identified,
transcriptionally active STAT3 site at -108. In conclusion, non-native pentameric human CRP is
an atheroprotective molecule whose ligand recognition functions exhibit similarity with CRP
from an evolutionarily distant species. IL-6 mediated transcriptional regulation of human CRP is
modulated, in part, by STAT3 binding to two distinct positions on the CRP promoter.
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CHAPTER 1
INTRODUCTION
C-reactive protein (CRP) is an acute phase protein of the human innate immune response
system that has been conserved during evolution. CRP was named so because it was discovered
to precipitate the C-polysaccharide of the pneumococcal cell wall (1). CRP belongs to the
phylogenetically conserved family of pentraxins and it falls in the category of short pentraxins
along with serum amyloid P (2). The primary ligand-binding specificity of CRP is for
phosphocholine (PCh)-containing substances, and this PCh-binding property of CRP is calcium
dependent (3). CRP pentamer has a recognition face, that contains binding sites for PCh and
calcium ions (Ca2+), and an effector face that lies opposite to the recognition face (4,5).
Structure of CRP
Human CRP is a pentamer composed of five identical non-covalently linked subunits
(Fig 1.1). Each subunit has a molecular weight of approximately 23 kDa and is composed of 206
amino acids. The five subunits of pentameric CRP are symmetrically arranged around a central
pore, with every subunit folded into two antiparallel b sheets forming a flattened jelly-roll
topology. Each subunit has a binding site for PCh, the primary ligand for CRP, and Ca2+. The
PCh-binding site lies on the recognition face of the CRP pentamer and it is made up of two
bound Ca2+ along with a hydrophobic pocket formed by three critical amino acids, Phe66, Thr76,
and Glu81. The phosphate group of PCh interacts with the two Ca2+ while the choline moiety of
PCh interacts with Phe66 (3 methyl groups of choline) and Glu81 (positively charged nitrogen
atom of choline). Thr76 indirectly participates in forming the PCh-binding site by creating an
appropriately sized hydrophobic pocket for PCh to fit (6-8).
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Phosphocholine
Ca2+

Figure 1.1: Crystal structure of CRP complexed with PCh in the presence of Ca2+. The
PCh moiety is represented in red while the Ca2+ are represented in green (Shrive AK, et
al., 1996, Nature Struct. Biol. 3:346: used with permission).

At the PCh-binding pocket, CRP also binds to phosphoethanolamine (PEt)-containing
substances, cholesterol, and histones (9,10). The face opposite to the recognition face, is the
effector face of the CRP pentamer. The effector face interacts with C1q, the classical
complement pathway protein, and Fcγ receptors via a cleft that extends from the center of each
subunit to the central pore. The amino acids critical for forming the C1q binding site on CRP are
Asp112 and Tyr175 (4,11-12). A slight conformational change is required in the CRP pentamer for
optimal binding of C1q to ligand-complexed CRP and the ligand to which CRP is complexed
determines the conformational change (13).
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Functions of CRP
CRP is a key component of the inflammatory response in humans and its association with
various disease pathologies such as atherosclerosis, pneumococcal infection, rheumatoid
arthritis, systemic lupus erythematosus (SLE), and cancer has been studied. It has been shown to
bind to substances containing exposed PCh-groups such as bacterial pneumococcal Cpolysaccharide, low-density lipoprotein (LDL), and apoptotic or damaged cells (14-16). Ligandcomplexed CRP activates the classical complement pathway via binding to C1q. This ligandbound CRP-C1q complex mediates the clearance of pathogens and cellular debris (4,11). In
addition to activation of complement, it also induces phagocytosis via indirect interaction with
Fcγ receptors on macrophages (12).
CRP has been shown to exist in two pentameric structural conformations: native and nonnative. Native pentameric CRP, at physiological pH, recognizes and binds to molecules with
exposed PCh-groups while non-native pentameric CRP recognizes and binds to immobilized
proteins exhibiting malformed or misfolded proteins in addition to binding to molecules with
exposed PCh-groups and this interaction occurs in conditions resembling inflammatory states
(17).
CRP has been shown to be protective against bacterial infection (Streptococcus
pneumoniae) where, in its native pentameric conformation it binds to the exposed PCh-groups on
the bacteria and then this ligand-complexed CRP binds to C1q and activates the classical
complement pathway mediating pathogen clearance. In this way, native CRP is protective
against early stages of pneumococcal infection (18-20). Non-native pentameric CRP, on the
other hand, binds to immobilized Factor-H along with binding to exposed PCh-groups on the
bacteria. Due to this dual functionality of non-native pentameric CRP, it is protective against
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both early and late stages of pneumococcal infection (21-22). In addition to protection against
Streptococcus pneumoniae, CRP has been shown to increase survival of mice injected with
Salmonella typhimurium (23).
The association of CRP with chronic inflammatory conditions such as atherosclerosis,
has been described in light of its increased serum levels (24). CRP has been shown to bind to
modified or atherogenic forms of LDL along with its co-localization with macrophages and
modified LDL at atherosclerotic lesions (25). In a study using a mouse model with human like
hypercholesterolemia, CRP has been shown to slow down the progression of atherosclerosis
(26). In a mouse model of SLE, human CRP was shown to prevent and reverse nephritis (27).
Also, CRP has been shown to protect myeloma cells from chemotherapy-induced apoptosis (28).

Significance of Serum CRP levels
CRP is an acute phase plasma protein in humans, concentration of which increases in
acute, chronic and some non-inflammatory conditions (29, 30). The serum concentration of CRP,
in a healthy individual, is 0.8-3 mg/L but, following the onset of an inflammatory state the
concentration of CRP increases rapidly (Fig. 1.2). This increase in serum concentration ranges
from 1-3 mg/L to several hundred and thousand-fold higher (31). Following the resolution of
inflammation, there is an equally rapid decrease in CRP concentration down to basal levels (32).
Therefore, for diagnosis of various acute and chronic inflammatory diseases, serum CRP levels
are used as a marker of inflammation.
Elevation of CRP concentration above baseline levels was recommended by the
American Heart Association to be used as a predictor for cardiovascular diseases such as
atherosclerosis (24). Due to variations in the serum CRP levels in healthy population, it is not
20

clear whether we can use elevated CRP levels as an independent risk factor for prediction,
diagnosis, and pathogenesis of any inflammatory disease (33,34).

Figure 1.2. Percent change in plasma concentrations of various acute phase proteins
following an inflammatory stimulus (Gabay C, et al., 1999, N. Engl. J. Med. 340, 448-54:
used with permission).

CRP and Atherosclerosis
Atherosclerosis is a chronic inflammatory disease that is initiated by the retention of
lipids along the arterial lining with subsequent modification of LDL. Modified LDLs, often
characterized as atherogenic LDL, are engulfed by macrophages, which then transform into
lipid-loaded foam cells. Foam cells are pro-inflammatory and initiate the process of lesion
formation (35). The generation of extracellular acidic environment, lipid retention, lipoprotein
modification, and conversion of macrophages into LDL-loaded foam cells are the hallmarks of
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such localized inflammatory atherosclerotic lesions. The development of an acidic extracellular
milieu may be due to macrophage activation, hypoxia, lactate generation and proton generation
(36-41).
CRP has been implicated in the pathogenesis of atherosclerosis, yet its function remains
undefined. Human CRP, apart from being present in the circulation, is also deposited in the
extracellular matrix of localized inflammatory sites such as atherosclerotic plaques in both
humans and animal models (42-45). Previous studies have examined the binding of native
pentameric CRP to two atherogenic forms of LDL: enzymatically modified LDL (E-LDL) and
oxidized LDL (ox-LDL). CRP binds to E-LDL at physiological pH in a Ca2+-dependent and
PCh-inhibitable manner. This binding is dramatically increased in the presence of acidic pH
(39,41). CRP does not bind to ox-LDL at physiological pH but gains the ability to bind to oxLDL at acidic pH. Acidic pH does not monomerize CRP, and the change in the binding is
reversible on pH neutralization. This binding of CRP to ox-LDL is not Ca2+-dependent,
indicating that acidic pH causes a conformational alteration of the CRP pentamer, and exposes a
functional site in CRP that is buried at physiological pH. Along with structural studies of CRP at
acidic pH, these results suggested that inter-subunit interactions were involved in the acidic pH
induced ‘loosening’ of the CRP pentamer (46).
In studies using animal models of atherosclerosis, native human CRP has not been shown
to have an effect on the initiation and progression of atherosclerosis (47-50). However, in vitro
studies have shown that CRP, in its alternate structural conformation, has the ability to bind to
modified atherogenic LDL, such as ox-LDL. CRP has also been shown to prevent macrophage
foam cell formation in vitro. Because the presence of an acidic environment is a hallmark of
atherosclerotic lesions, the absence of such inflammatory environment in these rodent models of
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atherosclerosis might explain the ineffectiveness of human CRP as the CRP administered to
these animals might not have undergone the low pH-induced structural modification that is
required for it to bind ox-LDL and prevent ox- LDL induced foam cell formation (51). In this
dissertation, in specific aim 1, the anti-atherosclerotic function of CRP in its non-native
pentameric structural conformation will be investigated.
Rationale and Hypothesis
Acidic pH transforms native pentameric CRP pentamer into a ‘loosened’ pentamer
confirmation and exposes the hidden ox-LDL binding site that was previously buried. As the pH
of the atherosclerotic lesion in animal models may not be acidic, to test the role of CRP in
atherogenesis it is essential to have a modified CRP that can bind to ox-LDL at physiological
pH. We hypothesize that site-directed mutagenesis of the amino acids involved in the intersubunit interactions will result in a ‘loosened’ pentamer that can bind to ox-LDL at physiological
pH. Such mutant CRP, created by site-directed mutagenesis, that displays the ability to bind to
ox-LDL at physiological pH can either prevent or delay the initiation and progression of
atherosclerosis.
Evolutionary Conservation of CRP
CRP is an evolutionarily conserved protein as, across the animal phyla, it has been found
in every organism where its presence has been sought (52) (Fig 1.3).The American horseshoe
crab Limulus Polyphemus, an arthropod, has been considered to be a living fossil as it diverged
approximately 300-500 million years ago and is the best characterized invertebrate source of
pentraxin proteins. In the hemolymph of Limulus Polyphemus, hemocyanin is the predominant
protein followed by pentraxins as the second most abundant protein. Amongst the pentraxins
CRP, SAP-like pentraxin, and limulin are present in the hemolymph of these animals (53). Three
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subunits of Limulus CRP have been established based on the amino acid sequence, disulfide
bonds and sites of glycosylation, that have been shown to exist in equimolar amounts (54).

Figure 1.3. Phylogenetic tree of CRP (Lee PT, et al., 2017, Fish Shellfish Immunol. 65,
42-51: used with permission).

During evolution, the structure of CRP changed. Unlike human CRP, which is a
pentamer, Limulus CRP is a stack of two hexamers composed of six identical subunits (~12
subunits) (54) although the region in human CRP that is critical for PCh-binding and Ca2+ ion
binding show sequence identity with Limulus CRP (55). Human CRP, in its native pentameric
conformation, binds to molecules and cells that have exposed PCh residues in a Ca2+-dependent
manner. Human CRP, in its alternate or non-native pentameric conformation recognizes an, as
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yet, undefined pattern on immobilized, aggregated and conformationally altered proteins. The
alternate structural conformation of CRP is achieved in response to inflammatory conditions
characterized by acidic pH and oxidative stress (17). As opposed to human CRP, Limulus CRP is
a glycoprotein. Published literature suggests that there are three distinct pentraxin species in
Limulus depending upon its PCh, PEt, and sialic acid binding properties: CRP, SAP-like protein,
and limulin respectively (54-59). Not much is known about the functions and the structurefunction relationships of Limulus CRP. Specific aim 2 of this dissertation is designed to explore
the functions of Limulus CRP.
Rationale and Hypothesis
These invertebrates lack an adaptive immune system, therefore humoral components such
as the pentraxins are implicated in non-specific host defense and innate immunity that has been
evolutionarily conserved. The discovery of Limulus CRP and its study provides important
insights in the evolution of pentraxins and subsequent divergence of function in comparison to
human CRP, over the period of time. The differences in the overall structure and glycosylation
states between invertebrate and vertebrate CRP indicate that the functions of CRP are also
specific. The evolutionary conservation of CRP from invertebrates to humans and its high
circulating concentration in an ancient invertebrate provides insight into the importance of CRP
and its biological functions. We hypothesize that, unlike human CRP, Limulus CRP does not
require a structural change to recognize and bind to pathogenic and toxic proteins formed due to
harsh environments where these arthropods live.
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Regulation of CRP gene expression
Like its structure, the level of CRP gene expression also changed during evolution. In
lower invertebrates such as the American horseshoe crab Limulus polyphemus, CRP is a
constitutively expressed protein and is present in the hemolymph at all times at high
concentration. In mice, CRP gene is expressed at a very low level. In rats, CRP is a minor acute
phase protein. In humans, CRP is the prototypic acute phase protein whose serum level increases
several folds in response to inflammatory conditions. CRP serves as a non-specific biomarker of
inflammation and its serum concentration is often measured to monitor the resolution of
inflammation. Currently, experiments are underway in several laboratories to understand the
mechanism of human CRP gene expression in hepatocytes (32, 40, 60-62).
Human CRP is a hepatic protein that is encoded by a single gene located on the short arm
of chromosome 1(62). Several hepatic cell lines such Hep3B, HepG2, and Huh7 are used to
study CRP gene expression as the availability of primary human hepatocytes is limited. Various
cytokines such as interleukin 6 (IL-6), interleukin 1β (IL-1β), TNFα, TGFβ, and IL-17 regulate
CRP gene expression via activation of specific transcription factors (63-67). Hep3B is the most
commonly use cell line model to study CRP gene expression and the cytokines that majorly
regulate gene expression in these cell lines are IL-6 and IL-1β (68). IL-6 increases CRP
transcription through activation of transcription factors CCAAT/enhancer-binding protein β
(C/EBPβ) and signal transducer and activator of transcription 3 (STAT3) (69-72). IL-1β is
insufficient by itself to activate CRP gene expression, however, when acting synergistically with
IL-6, it enhances the effects of IL-6 by activating the transcription factor nuclear factor-kappa B
(NF-κB) (73-75). Apart from these cytokine-activated transcription factors, CRP gene expression
is regulated by constitutively expressed transcription factors such as HNF-1, HNF-3, C/EBPδ,
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RBP-Jκ, and Oct-1 (76-81).
It has been shown that the proximal 157 bp region of the CRP promoter at the 5’ flanking
region is sufficient for the synergy between IL-6 and IL-1β and this region of the CRP promoter
contains binding sites for multiple transcription factors including cytokine-activated transcription
factors and constitutively expressed transcription factors. Previous studies have identified the
binding sites at which these transcription factors bind and induce and regulate CRP gene
expression (64,75,82) (Fig 1.4).

Figure 1.4. The -300 to +3 region of the proximal promoter region of the CRP gene is
shown. The binding sites of various transcription factors on the promoter are boxed
(adapted from Prem Prakash Singh et al., 2007, J Immunol. 178, 7302-09).

STAT3 is a major transcription factor activated by IL-6. STAT3 binds to specific
response elements in the promoter regions containing TT(N)4AA or TT(N)5AA motifs. A
functional, STAT3-binding site, centered at position -108 on the CRP promoter has been
previously identified when searched within the first 157 bp region of the promoter (83).
However, the data suggest that this STAT3 site is not the only site through which IL-6 activated
STAT3 works. STAT3 induces its effect by binding to both TT(N)4AA and TT(N)5AA
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sequences in the promoter. In specific aim 3 of this dissertation, we will identify putative
STAT3-binding sites in the 300 bp region of proximal CRP promoter and elucidate the role of
STAT3 in CRP gene expression.
Rationale and hypothesis
Previously, it has been reported that, in response to IL-6, the induction of CRP gene
expression driven by the first 300 bp region is higher than when driven by only 157 bp of the
promoter. We hypothesize that there are more STAT3-binding sites (besides the one present at
position -108) on the CRP promoter, likely to be located within the -157 to -300 bp region that
might participate in inducing and regulating CRP gene expression.
For better understanding the role of CRP in light of its structure-function relationship, we
had three major questions. The first question entailed to the function of a structurally altered
pentameric CRP (non-native CRP) in the initiation and progression of atherosclerosis, whose
ligand recognition function differs from native CRP. For the second question, we wanted to learn
if this structure-dependent ligand recognition function of human CRP diverged during evolution
by using CRP from an evolutionarily distant species, Limulus polyphemus. And lastly, for the
third question, we wanted to better understand the transcriptional regulation of CRP gene
expression by studying the function of an IL-6 inducible transcription factor, STAT3. These
questions were addressed through different projects that are stated in the specific aims below.
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Specific Aims

1.

Determine the atheroprotective ability of human CRP in a murine model of
atherosclerosis.
a. Identification of a CRP mutant created by site-directed mutagenesis which binds to
immobilized ox-LDL at physiological pH.
b. Determine the effects of the CRP mutant capable of binding to ox-LDL on the
development of atherosclerosis employing LDL receptor knockout mouse model of
atherosclerosis.
•

The findings are presented in Chapter 2

2. Purification and characterization of CRP from the hemolymph of Limulus Polyphemus.
a. Purification of PCh-binding and PEt-binding protein.
b. Deglycosylation of PCh-binding and PEt-binding proteins.
c. Define ligand-binding properties of native and deglycosylated PCh-binding and PEtbinding proteins.
•

The findings are presented in Chapter 3

3. Investigating the role of transcription factor STAT3 in human CRP expression in hepatic
cells.
a. Screening for STAT3-binding sites in the first 300 bp region on the CRP promoter.
b. Confirm the binding of STAT3 to the putative STAT3-binding sites identified.
c. Determine if any of the putative STAT3-binding sites are transcriptionally active.
•

The findings are presented in Chapter 4
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CRP is an atheroprotective molecule
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Abstract
Objective- C-reactive protein (CRP) is a pentameric, acute phase protein that exists in three
structural conformations: native pentameric, non-native pentameric, and monomeric. In vitro,
native CRP does not bind to oxidized LDL, however, non-native CRP binds to oxidized LDL as
it has been proposed that CRP changes its structure at sites of inflammation. In vivo, native CRP
is neither pro-atherosclerotic nor atheroprotective and we hypothesize that this ineffectiveness of
native CRP is due to an inappropriate inflammatory microenvironment in the arterial wall that
stalls CRP from changing its structure.
Methods and Results- In the current study, we evaluated the impact of a mutant CRP
F66A/T76Y/E81A CRP, that is capable of binding to oxidized LDL at physiological pH, on the
development of atherosclerosis. LDLR-/- mice were fed on a high fat diet for 10 weeks and
administered with and without F66A/T76Y/E81A CRP. We found that administration of
F66A/T76Y/E81A CRP significantly reduced the extent of atherosclerotic lesion in the whole
aorta and slowed the progression of atherosclerosis, but it did not show an effect on the
development and progression of atherosclerosis in the aortic root. F66A/T76Y/E81A CRP was
found to be localized in the atherosclerotic lesion in the aorta. Also, F66A/T76Y/E81A mutant
CRP administration did not alter the plasmid lipid levels.
Conclusion- F66A/T76Y/E81A CRP showed a site-specific atheroprotective effect via
dwindling atherosclerotic lesion development and progression in the aorta. Overall, the data
indicates that CRP is an atheroprotective molecule and such mutant CRP might represent as a
novel therapeutic tool for the treatment of atherosclerosis.
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Abbreviations:
ApoE-/ApoB100/100 LDLR-/-

Apolipoprotein E knockout
Apolipoprotein / low density lipoprotein receptor knockout

Ca2+

Calcium-ions

CRP

C-reactive protein

DI

Distilled water

E-LDL

Enzymatically modified low density lipoprotein

HDL

High density lipoprotein

HFD

High fat diet

LDL

Low density lipoprotein

LDLR-/-

Low density lipoprotein receptor knockout

mCRP

Monomeric C-reactive protein

mut CRP

F66A/T76Y/E81A mutant CRP

Ox-LDL

Oxidized low density lipoprotein

ORO

Oil Red O

PCh

Phosphocholine

TBS-Ca

TBS, pH 7.2, containing 0.1% gelatin, 0.02% Tween 20 and 2 mM CaCl2

WT

Wild-type
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Introduction
Atherosclerosis, an inflammatory disease of the heart, is caused by the dysfunction of the
endothelial wall leading to infiltration, deposition and subsequent modification of low-density
lipoprotein (LDL) along arterial lining (1-3). LDL, modified either by oxidation [oxidized LDL
(ox-LDL)], acetylation [acetylated LDL] or enzymatic modification [enzymatically modified
LDL (E-LDL)], is recognized and engulfed by macrophages to form foam cells. Modification of
LDL and formation of foam cells via macrophages are the two primary events marking the
hallmark of the development of atherosclerosis (3-5). Modified LDL has also been shown to
induce the expression of chemokines, pro-inflammatory cytokines, and other mediators of
inflammation at sites of atherosclerotic lesions. The pH in atherosclerotic lesions has also been
shown to be acidic due to proton and/or lactate generation, hypoxia, and activated macrophages
(6-10).
C-reactive protein (CRP) is an acute phase protein of hepatic origin. Structurally, it is a
pentamer of identical subunits, in which each subunit contains a phosphocholine (PCh)-binding
site and calcium ion (Ca2+)- binding site. It binds to PCh and PCh-containing ligands in a Ca2+dependent manner and Glu81, Phe66 and Thr76 are critical for this interaction. In a normal
physiological environment, CRP exists as native pentameric CRP, but upon exposure to a
localized pathological and inflammatory environment, it changes its structure to a non-native
pentameric state (11-17). This structural change of CRP from its native to non-native pentameric
state upon sensing of an inflammatory environment is reversible. Native CRP has been shown to
bind to E-LDL but not to ox-LDL. Its binding to ox-LDL is dependent on the presence of an
inflammatory microenvironment since CRP is able to change its native pentameric structure to a
non-native pentameric structure at acidic pH (18-23). In addition to this binding capability, it has
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also been found to co-localize with LDL and macrophages in atherosclerotic lesions in both
human and experimental animals, further suggesting a function in atherosclerosis (24-28).
Previously, native CRP has been investigated for its role in the development of
atherosclerosis using several different murine models of atherosclerosis such as ApoE -/(Apolipoprotein E knockout), LDLR -/- (LDL receptor knockout), and ApoB 100/100 LDLR -/(Apolipoprotein B100/100/. LDL receptor knockout). The conclusion of the studies was that CRP
was neither pro-atherogenic nor anti-atherosclerotic (29-32). One possible explanation for the
observed lack of effect of native CRP on atherosclerosis in these studies is that the mouse models
do not possess a suitable acidic microenvironment to induce native CRP to undergo structural
change to its non-native structural conformation.
In the present study, we examined the effect of F66A/T76Y/E81A mutant CRP (mut
CRP) on the development of atherosclerosis in LDLR-/- mice fed on a high fat diet (HFD). We
hypothesize that administration of this mut CRP, that binds to ox-LDL under physiological
conditions, would display beneficial effects on atherosclerosis in mice. In this study, we tested
this hypothesis by comparing the extent of atherosclerosis in HFD fed LDLR-/- mice, injected
with and without mut CRP. We found that administration of mut CRP significantly reduced the
en face atherosclerotic lesion area and slowed the progression of the disease in the whole aorta,
but, had no effect on the development of atherosclerosis in the aortic root. Overall, the data
indicate that administration of mut CRP does exibhit an atheroprotective effect in mice and it
further suggests that CRP in humans is a part of anti-atherosclerotic mechanism.
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Methods
Construction, Expression and Purification of mut CRP (F66A/T76Y/E81A Mutant CRP)
The construction of mut CRP has been described earlier (33). Briefly, a clone of
F66A/T76Y/E81A stably transfected in CHO cells was used for cell culture. Cells were cultured
in SFM media supplemented with 1% FBS and 1% Penicillin-Streptomycin stock and grown.
Media, containing mut CRP, was collected and centrifuged at 10,000 rpm for 10 minutes and
mut CRP was purified from cell culture supernatants by a Ca2+-dependent affinity
chromatography on a Phosphoethanolamine-conjugated Sepharose column followed by gel
filtration chromatography on a Superose 12 column, as described previously (33).
Ox-LDL Binding Assay
Binding activity of mut CRP for ox-LDL at physiological pH was evaluated by an
ELISA- based binding assay. Briefly, microtiter wells were coated with ox-LDL (10 µg/ml
diluted in 1X TBS) and incubated overnight at 4 °C. Wells were blocked with 0.5% gelatin for
45 minutes followed by addition of purified CRP [Wild type (WT) and mut CRP], diluted in
buffer containing 1X TBS, 0.1% gelatin, 0.02% Tween 20, and 2 mM CaCl2 (TBS-Ca, pH 7.2).
Wells were incubated with CRP for 2 h at 37 °C. Following CRP incubation, wells were washed
with TBS-Ca and rabbit anti-CRP antibody (Sigma, cat# C3527-1VL; diluted 1/1000 in TBSCa), was added (100 μl /well, 1 h at 37 °C) to detect bound CRP. HRP-conjugated donkey antirabbit IgG (GE Healthcare, cat# GENA934), diluted in TBS-Ca, was used (100 μl /well, 1 h at 37
°C) as the secondary antibody. Color was developed using ABTS as the substrate, and the
absorbance was read at 405 nm in a microtiter plate reader (Molecular Devices).
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Animal Procedures
Eight-week-old male LDLR-/- mice in the C57BL/6 background (#002207, Jackson
Laboratory, Bar Harbor, ME, USA) were placed on a HFD consisting of 21% fat and 0.2%
cholesterol (TD.88137; Envigo) for 10 weeks. After 1 week of HFD, mice were given injections
of mut CRP (50 µg/injection) every other day via alternating intra-venous (IV) and intraperitoneal (IP) routes for upto 9 weeks as depicted in (Fig 2.1). Control mice were injected with
an equivalent volume of vehicle (TBS). The dosage of mut CRP to be injected into mice was
decided on the basis of its rate of clearance, as previously performed pharmacokinetic studies
demonstrated the rate of clearance of mut CRP in vivo to be approximately 15-20 hours (33). At
two weeks intervals, groups (n=6) of mice were fasted overnight, anesthetized and anticoagulated blood samples were obtained by cardiac puncture prior to cardiac perfusion with icecold neutral buffered 10% formalin induced (Sigma, cat # HT-501128). Hearts and aortas were
cleared of adventitial fat and excised. Aortas were saved in 10% formalin at 40 C and heart tissue
was embedded in OCT medium and stored at -80 °C as done previously (34). All mice were
housed in a pathogen-free, temperature- and humidity-controlled room in the Animal Research
Facility at East Tennessee State University. All mice studies were approved by and conducted in
accordance with the guidelines administered by the Institutional Animal Care and Usage
Committee of East Tennessee State University and in conformity with the Public Health Service
Policy on Humane Care and Use of Laboratory Animals.
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Figure 2.1: A schematic representation of the protocol used during the study.

Analysis of Atherosclerosis
Atherosclerotic lesions throughout the thoracoabdominal aorta were evaluated in
formalin-fixed aortae opened longitudinally (en face) and stained with 0.5% Sudan IV, as
described previously (34). The extent of the total aortic lumen stained positive with Sudan IV
was quantified in digital images using Image J (35). For evaluation of atherosclerosis in the
aortic root , cross-section ( 8-µm) of frozen OCT-embedded heart tissue were collected on
microscope slides starting at the first appearance of the aortic valve leaflets until the
disappearance (~ 48-72 sections per mouse). Every other cross-section spanning the entire aortic
root were stained with Oil-red O (ORO) for lipids and counterstained with hematoxylin. Digital
photomicrographs were acquired with an Olympus BX41 microscope equipped with a CCD
color camera (QImaging) and the area staining positive for ORO was quantified using the Image
J software as previously described (34). All measurements were performed independently in a
blind fashion.
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Immunostaining
Formalin-fixed, Sudan IV stained aortae were first washed with water for 30 minutes
followed by alcohol dehydration through a series of graded alcohol washes. Aortae were washed
first with 70% alcohol for 30 minutes followed by 80% alcohol for 30 minutes, and then 95%
alcohol for 30 minutes. Post-dehydration, aortae were washed twice with xylene with each
xylene wash lasting for 30 minutes (36). Aortae were then washed with 1X PBS for 5 minutes
and immunostaining for mut CRP was performed using Vectastain ABC Elite kit (Vector
laboratories, cat # PK-6100) and manufacturer’s instructions were followed. Bound CRP was
detected with rabbit anti-CRP (Sigma, 10 µg/ml /aorta). Biotinylated goat-anti rabbit IgG was
used as the secondary antibody. Color was developed using two different peroxidase substrates:
Brown colored reaction produced by DAB (Vector laboratories, ImmPACT DAB, cat # SK4105) and blue colored reaction produced by TMB (Vector laboratories, cat # SK-4400).
Manufacturer’s instructions were followed.
Measurement of Lipids in the Plasma of LDLR-/- mice
Plasma was collected from whole blood via cardiac puncture at the time of sacrifice using
EDTA as an anti-coagulant. Plasma lipid levels [HDL (high density lipoprotein) and
LDL/VLDL] were analyzed using Cholesterol Assay Kit- HDL and LDL/VLDL (abcam; cat #
ab65390). Lipid levels were measured in the pooled plasma samples at every given week point
and manufacturer’s instructions were followed.
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Data Analysis
For atherosclerosis samples, data were analyzed using non-parametric test (MannWhitney test) using Graphpad Prism software. p < 0.05 was considered statistically significant.
For plasma lipid analysis, data is represented as mean + standard deviation and unpaired student
t-test was used to analyze statistically significant differences. p < 0.05 was considered
statistically significant.
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Results
F66A/T76Y/E81A Mutant CRP Binds to ox-LDL at Physiological pH
As shown previously (33), the overall structure of mut CRP was pentameric and the
mutation did not affect the stability of the protein in vivo. Additionally, mut CRP was found to
circulate freely in the mouse serum. The binding activity of mut CRP and WT CRP for ox-LDL
at physiological pH was assessed and mutant CRP bound to ox-LDL in a dose dependent manner
at physiological pH (pH 7.2). As expected, WT CRP did not bind to ox-LDL at physiological pH
(Fig 2.2).

Mut CRP
1.25

A 405

1.00
0.75
0.50

WT CRP

0.25

0.1

10

1
CRP (µg/ml)

Figure 2.2: F66A/T76Y/E81A mutant CRP binds to ox-LDL at physiological pH unlike
WT CRP. Microtiter wells were coated with ox-LDL. WT CRP (red) and mut CRP
(black) diluted in TBS-Ca were then added to the wells in increasing concentration.
Bound CRP was detected by using rabbit anti-CRP antibody and HRP-conjugated donkey
anti-rabbit IgG.
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This result show that mut CRP has the ability to recognize and bind to ox-LDL in vitro,
in the absence of an acidic environment. Furthermore, this binding is PCh-independent since the
PCh binding site of mut CRP is abolished (33).
Chronic Treatment with F66A/T76Y/E81A Mutant CRP Significantly Reduces
Atherosclerotic Lesion Formation in the Aortae of LDLR-/- mice
To assess the potential therapeutic effects of mut CRP on atherosclerotic burden in the
early stages of atherosclerosis, LDLR-/- mice were fed on HFD for 1 week and randomly
assigned to receive injections of vehicle or mut CRP (50 µg/injection). The experiment was
performed twice with n = 6 mice in each group at every given data collection time point. In the
first set of experiment, administration of mut CRP had no effect on the degree of atherosclerotic
lesion throughout the aorta at 1, 3, and 5 weeks. However, after 7 and 9 weeks of mut CRP
treatment, the total atherosclerotic lesion area was significantly lower when compared to the
lesion area in untreated mice (Fig 2.3 B). In comparison to untreated mice, the median aortic
lesion area was reduced by 29% after 7 weeks (p = 0.05) and 33% after 9 weeks (p = 0.002) in
mice injected with mut CRP. After 5 weeks, the atherosclerotic lesion area was 15% less in mut
CRP treated mice when compared to untreated mice, however the reduction did not reach
statistical significance (p = 0.06). In untreated group, the burden of atherosclerotic degree
progressed in an incremental manner from week 1 through week 7, where it reached a plateau
and remained constant at week 9. In contrast, progression of atherosclerosis in mice treated with
mut CRP also progressed incremently until week 5, but it reached a plateau and remained
constant at week 9.
In a replicate experiment, treatment with mut CRP did not affect the burden of
atherosclerotic lesion area at early time points (1, 3, and 5 weeks) but, resulted in a statistically
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significant reduction in aortic lesion area when compared to untreated mice (Fig 2.3 C). In
comparison to the untreated mice, the lesion area in mice treated with mut CRP was reduced by
52% after 7 weeks (p = 0.04) and 55% after 9 weeks (p = 0.03). Similar to the first experiment,
atherosclerosis steadily increased in the untreated mice from week 1 through week 9 but similar
disease progression was not observed in mice treated with mut CRP where the disease
progressed from week 1 through week 5 and stayed almost constant until week 9.
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Figure 2.3: F66A/T76Y/E81A mutant CRP reduces atherosclerosis in the aorta of
LDLR−/−mice. Quantification of total atherosclerotic lesion area in en face aorta
specimens from untreated and mut CRP treated LDLR−/− mice maintained on a high fat
diet. A, A representative Sudan IV-stained aorta from male LDLR−/− mice maintained on
a high fat diet demonstrating the spectrum of atherosclerosis is shown. The bright red
colored areas reflect the atherosclerotic plaque or lesion (lipid rich deposits) in the aorta.
Scale bar, 5 mm. B, Total atherosclerotic lesion coverage in en face aorta specimens from
untreated and mut CRP treated LDLR−/− mice while C, Quantification of total
atherosclerotic lesion coverage in en face aorta specimens from duplicate groups of
untreated and mut CRP treated LDLR−/− mice. Data was collected at 5 different time
points, i.e, 1, 3, 5, 7, and 9 weeks of mut CRP administration at alternate days (TBS was
injected for untreated group). A scatterplot of total atherosclerotic lesion coverage is
shown. Each symbol represents the total area of the entire aorta lumen that stained
positive with Sudan IV. Values for untreated mice are indicated in blue and those for mut
CRP treated are indicated in green. Horizontal lines indicate the median total lesion area
for each group. Asterisks (red) denote statistically significant differences between groups
(*p < 0.05).

These data, from two independently performed experiments, suggest that chronic
treatment with mut CRP reduces the extent of atherosclerosis in the aortae of HFD fed LDLR-/mice and slowed down the progression of the disease after 5 weeks of mut CRP administration.
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Atherosclerosis in the Aortic Root of LDLR-/- mice is Unaffected by Chronic Treatment
with F66A/T76Y/E81A Mutant CRP
We also investigated the effects of chronic administration of mut CRP on the
development of atherosclerosis at the level of the aortic root in two independent experiments.
The experiments were performed with n = 6 mice in each group at every given week time point.
In the first experiment, the median lesion area in the aortic root of mice receiving mut CRP
injections (every alternate day) was comparatively less than that of the corresponding control
mice, at all timepoints as determined by evaluation of ORO-stained cross-sections. However, the
decreases in the aortic root lesion areas of mice treated with mut CRP did not reach statistical
significance for any time point. Interestingly, although mut CRP did not significantly decrease
the size of aortic root atherosclerotic lesion area, it did delay the progression of the disease by
approximately two weeks as the lesion area at 5 week and 9 weeks of mut CRP administration
was similar to the lesion area at 3 and 7 weeks of untreated mice respectively (Fig 2.4 B). In the
second experiment, administration of mut CRP did not have any affect on the atherosclerotic
lesion area in the aortic root at any given time point (Fig 2.4 C). The data, from the first
experiment, suggest that mutant CRP delayed the progression of atherosclerosis in the aortic root
of LDLR-/- mice and the data from the second experiment suggest that mutant CRP had no effect
on atherosclerosis in the aortic root of LDLR-/- mice. Hence, the combined data suggest that
chronic administration of mut CRP had no effect on the development of atherosclerosis in the
aortic root of LDLR-/- mice.
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Figure 2.4: F66A/T76Y/E81A mutant CRP did not affect the development of
atherosclerosis in the aortic root of LDLR−/−mice. A, A representative ORO-stained aortic
root section from male LDLR−/− mice maintained on a high fat diet demonstrating the
spectrum of atherosclerosis is shown. The red colored areas reflect the atherosclerotic
lesion (lipid rich deposits) in the aortic root. Scale bar, 100 μm. Quantification of total
lesion area in the aortic root sections from untreated and mut CRP treated LDLR−/− mice
maintained on a high fat diet from two independent experiments is shown (B and C
respectively). Data was collected at 5 different time points (1, 3, 5, 7, and 9 weeks of mut
CRP administration). A scatterplot of total atherosclerotic lesion coverage in the aortic
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root is shown. Each symbol represents the aortic root lesion area determined for untreated
(blue) and mut CRP treated (green) LDLR−/− mouse. Horizontal black lines indicate the
median of total aortic root lesion area for each group of animals.

F66A/T76Y/E81A mutant CRP is Detected in Atherosclerotic Lesions of LDLR-/- mice
As shown above (Fig 2.4), chronic administration of mut CRP decreased the progression
of atherosclerosis in the aortae of LDLR-/- mice. To elucidate, if the observed effect of reduced
atherosclerosis in the lesions was due to chronic treatment with mut CRP, we performed, CRP
immunostaining of aortae in both untreated and mut CRP treated mice (Fig 2.5). anti-CRP
antibodies showed positive staining in atherosclerotic lesions of mice treated with mut CRP (Fig
2.5 A and 2.5 B). In comparison, no staining was observed with anti-CRP antibodies in the
atherosclerotic lesion of aorta of untreated mice (Fig 2.5 A and 2.5 B). This result shows that
chronic administration of mut CRP results in deposition of mut CRP within lesions, where it
might be bound to modified lipoproteins.
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Figure 2.5: F66A/T76Y/E81A mutant CRP accumulation in atherosclerotic lesions of
LDLR−/− mice. Representative aorta from untreated and mutant CRP treated LDLR−/−
mice subjected to immunostaining for CRP are shown. Panel 1-4 depicts an en face aorta
through different stages of staining procedures. (1) After Sudan IV staining to visualize
atherosclerotic lesions. Red stained areas reflect positive atherosclerotic lesions (lipid
rich deposits) in the aorta. (2) Aorta after destaining to remove Sudan IV. White colored
areas reflect positive atherosclerotic lesion in the aorta. (3) Following staining for CRP.
Brown stained areas are positive for CRP. (4) Enlarged view of aortic arch of the aorta
showing CRP positive staining. A, CRP stained aorta using DAB as substrate that
produces a brown colored reaction. B, CRP stained aorta using TMB as substrate that
produces a blue colored reaction.. Scale bar, 5 mm.
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F66A/T76Y/E81A mutant CRP did not Affect the Plasma Lipids Levels of LDLR-/- mice
In order to induce the development of atherosclerosis, LDLR-/- mice were fed HFD for 10
weeks. Chronic administration of mut CRP had no effect on the plasma LDL and HDL levels. At
the dose and delivery route employed, no significant difference in plasma lipid levels (both LDL
and HDL) were observed between untreated and mut CRP treated mice at any of the time points
examined (Table 2.1). In addition, mut CRP administration did not affect LDLR-/- mice body
weight as the body weights of untreated and mut CRP treated mice were in the same range (data
not shown).

Week of
sacrifice

HDL (mg/dL)

LDL (mg/dL)

Untreated

CRP-treated

Untreated

CRP-treated

1

61 ± 2

85 ± 19

864 ± 16

713 ± 31

3

91 ± 15

71 ± 19

838 ± 231

786 ± 246

5

78 ± 4

74 ± 12

754 ± 118

834 ± 185

7

131 ± 1

107 ± 15

932 ± 86

1086 ± 23

9

80 ± 3

105 ± 2

1054 ± 3

1103 ± 19

Table 2.1: Plasma HDL and LDL levels after treatment with and without
F66A/T76Y/E81A mutant CRP. Samples were collected at 6 different time points, i.e, 1,
3, 5, 7, and 9 weeks of mut CRP administration, as indicated. Data is shown as Mean +
SE in pooled samples from two independent experiments (n = 6/group).

48

Mut CRP has been shown to bind to modified lipoproteins such as ox-LDL, however the
observation that plasma lipid levels were unaffected by mut CRP administration suggests that
mut CRP did not bind or affect lipoproteins in fluid phase circulation. These data shows that the
reduction of atherosclerosis exhibited by mut CRP was likely not due to an effect on plasma
lipoprotein metabolism.
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Discussion
In this study we investigated the effect of a non-native pentameric CRP created by sitedirected mutagenesis, F66A/T76Y/E81A mutant CRP, that does not bind to PCh since the PCh
binding site of this mutant CRP is abolished due to mutations of critical amino acids forming the
PCh-binding pocket, i.e., Glu81, Phe66 and Thr76, on the development of atherosclerosis
employing LDL receptor knockout mouse model of atherosclerosis. Our major findings were as
follows: 1) Mut CRP, unlike WT CRP, binds to ox-LDL (one of the modified forms of LDL) at
physiological pH and it does not need the presence of an acidic environment to do so. Also, this
binding is PCh-independent since its PCh binding site is abolished. 2) Chronic administration of
mut CRP had an effect on the development and progression and of atherosclerosis throughout the
aorta as evidenced by significantly reduced atherosclerotic lesion in en face aorta of LDLR-/mice and halted progression of the disease post 5 weeks of mut CRP administration. 3)
Administration of mut CRP did not affect the atherosclerotic lesion area in the aortic root of
LDLR-/- mice. 4) Mut CRP administration did not affect the plasma lipid (HDL and LDL) levels
of LDLR-/- mice.
Native pentameric CRP does not recognize and bind to immobilized, aggregated, and
pathogenic proteins but it binds to cells and molecules with PCh groups exposed on its surface,
in a Ca2+-dependent manner (37-39). However, upon sensing a micro-inflammatory
environment, CRP tends to gain the ability to change its pentameric structure from a native
conformation to a non-native conformation (40). This structural conformation change, in vitro,
can be attained by exposure to biological modifiers such as hydrogen peroxide, hypochlorous
acid or even acidic pH but this structural change is reversible, i.e., as soon it senses physiological
pH, it reverts back to its native pentameric conformation (18-19, 41-42). Non-native pentameric
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CRP acquires the property to recognize and bind to immobilized, aggregated, and pathogenic
proteins as its recognition function changes in comparison to native pentameric CRP (17, 40).
For example, one of the functions of CRP in its non-native pentameric conformation is to bind to
modified LDL irrespective of the presence of PCh and Ca2+. Native CRP binds E-LDL, but not
ox-LDL. It binds to ox-LDL only if the LDL is sufficiently oxidized to expose its PCh moiety
and hence, it recognizes and binds to the exposed PCh moiety on ox-LDL. On contrary, nonnative CRP binds to E-LDL with higher avidity compared to native CRP and it binds to ox-LDL
irrespective of the oxidation extent of ox-LDL (18-19, 23,41,43-45).
The effects of supplementing native CRP has been investigated using three different
murine models of atherosclerosis (ApoE-/-, LDLR-/- and ApoB100/100 LDLR-/-) as well as a rabbit
model of atherosclerosis. Supplementation of native CRP produced no effect on the development
of atherosclerosis indicating it was neither pro-atherogenic nor anti-atherogenic (30-32, 45-53).
However, native CRP was shown to slow the development of atherosclerosis in one study
employing ApoB100/100 LDLR-/- mouse model, wherein these mouse models are rich in LDL and
have been shown to develop human-like hypercholesterolemia, suggesting that CRP might have
an atheroprotective role (29). Although investigations to determine the effects of native CRP on
the development of atherosclerosis in animal models provided conflicting results, a study for
investigating the effect of monomeric CRP (mCRP) on atherosclerosis using ApoE-/- mice
showed that mCRP was atheroprotective (52). Collectively, the data suggest that native
pentameric CRP was either incapable or only partly capable for protecting against atherosclerosis
in animal models. One of the potential reasons for the ineffectiveness of native CRP to affect
atherosclerosis development and progression in these murine models is that the mouse models
does not have the required inflammatory microenvironment, needed by CRP to change its
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structure and therefore bind to modified LDL. In support of this, data obtained from in vitro
studies revealed a non-native pentameric CRP, whose LDL-binding recognition functions differs
from native pentameric CRP (54).
In the current study, we used a modified CRP, F66A/T76Y/E81A mutant CRP, designed
by site-directed mutagenesis to mimic the properties of non-native pentameric CRP at
physiological pH. This mut CRP was tested found to recognize and bind to ox-LDL, one of the
modified forms of LDL, even in the absence of an acidic environment in a PCh-independent
manner. Next, we studied the effect of chronic administration of mut CRP on the development
and progression of atherosclerosis using HFD fed LDLR-/- mice in two independently performed
experiments. We found that the size of atherosclerotic lesions in the aorta of mut CRP treated
mice was reduced in comparison to the untreated mice. This effect was observed after 7 weeks of
mut CRP administration at every alternate day. In addition, we observed that the progression of
atherosclerosis was halted post 5 weeks of chronic mut CRP administration. The results obtained
were consistent between the two independently performed experiments even though the disease
was observed to be more aggressive in the second experiment when compared to the first
experiment, but still mut CRP was able to take care of it. However, no such effect was observed
when the extent of atherosclerosis was assessed in the aortic root area except, that, in the first
experiment chronic mut administration of CRP slowed the progression of the disease but, it
could not be replicated in the second experiment.
Such site-specific effects have been observed in various atherosclerotic studies using
LDLR-/- mouse models wherein experimental manipulations exhibit development of the disease
differently at different lesion-prone sites of the vasculature (55-59). Specifically, mut CRP was
shown to be atheroprotective in the whole aorta but neither pro-atherosclerotic nor anti-
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atherosclerotic in the aortic root. There were no region-specific effects observed in the different
regions of aorta, i.e., aortic arch, thoracic and abdominal regions. Because the disease
progression was studied in the earlier stages, the lesions formed mostly in the aortic arch area
and were only sporadically observed in the thoracic aorta. Although the aortic root may provide
significant information on lesion initiation and progression, its lesion responses are not
invariably reflective of the lesions throughout the whole aorta. The observed beneficial effects of
mut CRP on atherosclerosis outside of the aortic root may reflect unknown region-specific
functions of CRP. Alternatively, it is possible that the ability of mut CRP to retard lesion
formation is too subtle to overcome the aggressive atherogenesis induced in the aortic root by the
HFD employed in our study, i.e., the rate of lesion formation in the whole aorta is slower in
comparison to aortic root and therefore, mut CRP is able to exhibit an observable effect.
The co-localization of native CRP with macrophages and LDL in atherosclerotic lesions
in the aortic root has been reported. Modified LDL (ox-LDL, and E-LDL) have been shown to
induce the formation of foam cells via uptake by macrophages. (5, 60-66). Because in the current
study, mut CRP showed an atheroprotective effect in the whole aorta, we determined the
presence of administered mut CRP at atherosclerotic lesion in the whole aorta and we found that
mut CRP was localized in the en face atherosclerotic lesion. This suggest that mut CRP colocalizes with LDL at the atherosclerotic lesion in the whole aorta. We hypothesize a mechanism
for the atheroprotective effect exhibited by mut CRP, where mut CRP recognizes and interacts
with modified LDL at the atherosclerotic lesions and prevents the formation of foam cells by
blocking the uptake of LDL by macrophages. This hypothesized mechanism, although yet to be
studied, is in accordance with a previously published study, where they reported that in vitro
CRP-bound E-LDL prevents the transformation of macrophages to foam cell (67). The
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atheroprotective effect of mut CRP in the whole aorta was observed in the absence of any
observable changes in the plasma lipid (HDL and LDL) concentrations suggesting that mut CRP
did not bind or had any effect on the lipoproteins in fluid phase.
As discussed above, the co-localization of CRP with LDL and its deposition in
atherosclerotic lesions indicates the presence of a structurally altered or non-native CRP at the
lesions. Interaction of LDL with CRP is mediated through PCh, apolipoprotein B and,
cholesterol moieties (68-70). The moiety on modified LDL and the binding site on non-native
pentameric CRP with which this interaction is mediated, is still unknown. One of the possible
binding sites involved in this interaction might be the inter-subunit contact region in CRP since
this region is inaccessible in native CRP but accessible in non-native CRP (18, 40). Another
possible binding site involved in this interaction might be the cholesterol binding sequence
(amino acid 35 to 47) since it has been found that to mediate the interactions of monomeric CRP
with diverse ligands (71). In conclusion, non-native pentameric CRP such as in vitro-modified
CRP (F66A/T76Y/E81A mutant CRP) binds to modified LDL without the requirement of an
inflammatory microenvironment and shows a site-specific atheroprotective effect by decreasing
the size of atherosclerotic lesion in the whole aorta post 8 weeks of high fat diet and halted the
progression of atherosclerosis post 6 weeks of high fat diet. This study provides a proof of
principle for the ability of a mut CRP to be further described as an atheroprotective molecule.
Since, this is a single dose-one model regimen, further studies are required to define potential
mechanisms that are responsible for the observed protective effect of CRP on atherosclerosis.
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Highlights:
1. A triple mutant CRP ( F66A/T76Y/E81A mutant CRP), locked in an alternate pentameric
structural conformation, binds to oxidized LDL at physiological pH.
2. Chronic administration of F66A/T76Y/E81A mutant CRP, decreased atherosclerotic
lesion development and progression in a site-specific manner, wherein it decreased
atherosclerotic lesion in whole aorta but had no effect in the aortic root.
3. F66A/T76Y/E81A mutant CRP or CRP in its non-native pentameric conformation is an
atheroprotective molecule and represents a potential novel therapy for the treatment of
atherosclerosis.

Acknowledgement
The work was supported by NIH Grant: R01 AR068787 (Agrawal ; P.I.)

55

References
1. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868-874.
2. Galkina E, and Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu
Rev Immunol. 2009; 27:165-197.
3. Lu H, and Daugherty A. Atherosclerosis: Cell Biology and lipoproteins. Curr Opin
Lipidol. 2013; 24: 455-456.
4. Moore KJ, and Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;
145: 341-355.
5. Orsó E, Grandl M, and Schmitz G. Oxidized LDL-induced endolysosomal
phospholipidosis and enzymatically modified LDL-induced foam cell formation
determine specific lipid species modulation in human macrophages. Chem Phys Lipids.
2011; 164: 479-487.
6. Leake DS. Does an acidic pH explain why low density lipoprotein is oxidised in
atherosclerotic lesions? Atherosclerosis. 1997; 129: 149-157.
7. Björnheden T, Levin M, Evaldsson M, and Wiklund O. Evidence of hypoxic areas within
the arterial wall in vivo. Arterioscler Thromb Vasc Biol. 1999; 19: 870-876.
8. Naghavi M, John R, Naguib S, Siadaty MS, Grasu R, Kurian KC, van Winkle WB, Soller
B, Litovsky S, Madjid M, Willerson JT, and Casscells W. pH heterogeneity of human
and rabbit atherosclerotic plaques: A new insight into detection of vulnerable plaque.
Atherosclerosis. 2002; 164: 27-35.
9. Sneck M, Kovanen PT, and Öörni K. Decrease in pH strongly enhances binding of
native, proteolyzed, lipolyzed, and oxidized low density lipoprotein particles to human
aortic proteoglycans. J Biol Chem. 2005; 280: 37449-37454.

56

10. Haka AS, Grosheva I, Chiang E, Buxbaum AR, Baird BA, Pierini LM, and Maxfield FR.
Macrophages create an acidic extracellular hydrolytic compartment to digest aggregated
lipoproteins. Mol Biol Cell. 2009; 20: 4932-4940.
11. Ji SR, Wu Y, Zhu L, Potempa LA, Sheng F-L, Lu W, and Zhao J. Cell membranes and
liposomes dissociate C-reactive protein (CRP) to form new, biologically active structural
intermediate: mCRPm. FASEB J. 2007; 21: 284-294.
12. Agrawal A, Gang TB, and Rusiñol AE. Recognition functions of pentameric C-reactive
protein in cardiovascular disease. Mediators Inflamm. 2014; 2014: 319215.
13. Wu Y, Potempa LA, El Kebir D, and Filep JG. C-reactive protein and inflammation:
Conformational changes affect function. Biol Chem. 2015; 396: 1181-1197.
14. Braig D, Nero TL, Koch H-G, Kaiser B, Wang X, Thiele JR, Morton CJ, Zeller J, Kiefer
J, Potempa LA, Mellett NA, Du XJ, Meikle PJ, Huber-Lang M, Stark GB, Parker MW,
Peter K, and Eisenhardt SU. Transitional changes in the CRP structure lead to the
exposure of proinflammatory binding sites. Nat Commun. 2017; 8:14188.
15. McFadyen JD, Kiefer J, Braig D, Loseff-Silver J, Potempa LA, Eisenhardt SU, and Peter
K. Dissociation of C-reactive protein localizes and amplies inflammation: Evidence for a
change direct biological role of C-reactive protein and its conformational changes. Front
Immunol. 2018; 9: 1351.
16. Salazar J, Martinez MS, Chávez-Castillo M, Núñez V, Añez R, Torres Y, Toledo A,
Chacín M, Silva C, Pacheco E, Rojas J, and Bermúdez V. C-reactive protein: An in-depth
look into structure, function, and regulation. Intl Sch Res Notices. 2014; 2014: 653045.
17. Lv J-M, and Wang M-Y. In vitro generation and bioactivity evaluation of C-reactive
protein intermediate. PloS One. 2018; 13: e0198375.

57

18. Hammond DJ Jr, Singh SK, Thompson JA, Beeler BW, Rusiñol AE, Pangburn MK,
Potempa LA, and Agrawal A. Identification of acidic pH-dependent ligands of
pentameric C-reactive protein. J Biol Chem. 2010; 285: 36235-36244.
19. Singh SK, Thirmulai A, Pathak A, Ngwa DN, and Agrawal A. Functional transformation
of C-reactive protein by hydrogen peroxide. J Biol Chem. 2017; 292: 3129-3136.
20. Bhakdi S, Torzewski M, Klouche M, and Hemmes M. Complement and atherogenesis:
Binding of CRP to degraded, nonoxidized LDL enhances complement activation.
Arterioscler Thromb Vasc Biol. 1999; 19: 2348-2354.
21. He W, Ren Y, Wang X, Chen Q, and Ding S. C-reactive protein and enzymatically
modified LDL cooperatively promote dendritic cell-mediated T cell activation.
Cardiovasc Pathol. 2017; 29: 1-6.
22. De Beer FC, Soutar AK, Baltz ML, Trayner IM, Fienstein A, and Pepys MB. Low
density lipoprotein and very low density lipoprotein are selectively bound by aggregated
C-reactive protein. J Exp Med. 1982; 156: 230-242.
23. Ji S-R, Wu Y, Potempa LA, Qiu Q, and Zhao J. Interaction of C-reactive protein with
low-density lipoproteins: Implications for an active role of modified C-reactive protein in
atherosclerosis. Int J Biochem Cell Biol. 2006; 38: 648-661.
24. Torzewski J, Torzewski M, Bowyer DE, Fröhlich M, Koenig W, Waltenberger J,
Filtzsimmons C, and Hombach V. C-reactive protein frequently colocalizes with the
terminal complement complex in the intima of early atherosclerotic lesions of human
coronary arteries. Arterioscler Thromb Vasc Biol. 1998; 18: 1386-1392.

58

25. Zhang YX, Cliff WJ, Schoefl GI, and Higgins G. Coronary C-reactive protein
distribution: Its relation to development of atherosclerosis. Atherosclerosis. 1999; 145:
275-379.
26. Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, Kitajima S, Morimoto
M, Watanabe T, Asada Y, Chen YE, and Fan J. C-reactive protein in atherosclerotic
lesions: Its origin and pathophysiological significance. Am J Pathol. 2005; 167: 11391148.
27. Norja S, Nuutila L, Karhunen PJ, and Goebeler S. C-reactive protein in vulnerable
coronary plaques. J Clin Pathol. 2007; 60: 545-8.
28. Yu Q, Li Y, Wang Y, Zhao S, Yang P, Chen Y, Fan J, and Liu E. C-reactive protein
levels are associated with the progression of atherosclerotic lesions in rabbits. Histol
Histopathol. 2012; 27: 529-535.
29. Kovacs A, Tornvall P, Nilsson R, Tegnér J, Hamsten A, and Björkegren J. Human Creactive protein slows atherosclerotic development in a mouse model with human-like
hypercholesterolemia. Proc Natl Acad Sci USA. 2007; 104: 13768-13773.
30. Koike T, Kitajima S, Yu Y, Nishijima K, Zhang J, Ozaki Y, Morimoto M, Watanabe T,
Bhakdi S, Asada Y, Chen YE, and Fan J. Human C-reactive protein does not promote
atherosclerosis in transgenic rabbits. Circulation. 2009; 120: 2088-2094.
31. Teupser D, Weber O, Rao TN, Sass K, Thiery J, and Fehling HJ. No reduction of
atherosclerosis in C-reactive protein (CRP)-deficient mice. J Biol Chem. 2011; 286:
6272-6279.
32. Yu Q, Liu Z, Waqar AB, Ning B, Yang X, Shiomi M, Graham MJ, Crooke RM, Liu E,
Dong S, and Fan J. Effects of antisense oligonucleotides against C-reactive protein on the

59

development of atherosclerosis in WHHL rabbits. Mediators Inflamm. 2014; 2014:
979132.
33. Gang TB, Hammond DJ Jr, Singh SK, Ferguson DA Jr, Mishra VK, and Agrawal A. The
phosphocholine-binding pocket on C-reactive protein is necessary for initial protection of
mice against pneumococcal infection. J Biol Chem. 2012; 287(51): 43116-43125.
34. Netherland CD, Pickle TG, Bales A, and Thewke DP. Cannabinoid receptor type 2 (CB2)
deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice.
Atherosclerosis. 2010; 213(1):102-8.
35. Schneider CA, Rasband WS, and Eliceiri KW. NIH Image to ImageJ: 25 years of image
analysis. Nat Methods. 2012; 9(7):671-5.
36. Fu Z, Yan K, Rosenberg A, Jin Z, Crain B, Athas G, Heidi RS, Howard T, Everett AD,
Herrington D, and Van Eyk JE. Improved protein extraction and protein identification
from archival formalin-fixed paraffin-embedded human aortas. Proteomic Clin Appl.
2013; 7(3-4):217-24.
37. Volanakis JE, and Kaplan MH. Specificity of C-reactive protein for choline phosphate
residues of pneumococcal C-polysaccharide. Pros Soc Exp Biol Med. 1971;136:612-614.
38. Volanakis JE, and Wirtz KWA. Interaction of C-reactive protein with artificial
phosphatidylcholine bilayers. Nature. 1979; 281:155-157.
39. Black S, Wilson A, and Samols D. An intact phosphocholine binding site is necessary for
transgenic rabbit C-reactive protein to protect mice against challenge with plateletactivating factor. J Immunol.2005; 175: 1192-1196.
40. Agrawal A, Gang TB, and Rusiñol AE. Recognition functions of pentameric C-reactive
protein in cardiovascular disease. Mediators Inflamm. 2014; 2014: 319215.

60

41. Singh SK, Hammond DJ Jr, Beeler BW, and Agrawal A. The binding of C-reactive
protein, in the presence of phosphoethanolamine, to low-density lipoproteins is due to the
phosphoethanolamine-generated acidic pH. Clin Chim Acta. 2009; 409: 143-4.
42. Boncler M, Kehrel B, Szewczyk R, Stec-Martyna E, Bednarek R, Brodde M, and Watala
C. Oxidation of C-reactive protein by hypochlorous acid leads to the formation of potent
platelet activating factor. Int J Biol Macromol. 2018; 107: 2701-2714.
43. Chang M-K, Binder CJ, Torzewski M, and Witztum JL. C-reactive protein binds to both
oxidized LDL and apoptotic cells through recognition of a common ligand:
Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA. 2002; 99: 1304313048.
44. Biró A, Thielens NM, Cervenák L, Prohászka Z, Füst G, and Arlaud GJ. Modified low
density lipoproteins differentially bind and activate the C1 complex of complement. Mol
Immunol. 2007; 44: 1169-1177.
45. Bian F, Yang X, Zhou F, Wu P-H, Xing S, Xu G, Li W, Chi J, Ouyang C, Zhang Y,
Xiong B, Li Y, Zheng T, Wu D, Chen X, and Jin S. C-reactive protein promotes
atherosclerosis by increasing LDL transcytosis across endothelial cells. Br J Pharmacol.
2014; 171: 2671-2684.
46. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM,
Dhillon AP, Tennent GA, and Pepys MB. Transgenic human C-reactive protein is not
proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA. 2005; 102:
8309-8314.
47. Reifenberg K, Lehr H-A, Baskal D, Wiese E, Schaefer SC, Black S, Samols D,
Torzewski M, Lackner KJ, Husmann M, Biettner M, and Bhakdi S. Role of C-reactive

61

protein in atherogenesis: Can the apolipoprotein E knockout mouse provide the answer?
Arterioscler Thromb Vasc Biol. 2005; 25: 1641-1646.
48. Trion A, de Matt MPM, Jukema JW, van der Laarse A, Mass MC, Offerman EH,
Havekes LM, Szalai AJ, Princen HM, and Emeiss JJ. No effect of C-reactive protein on
early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein
transgenic mice. Arterioscler Thromb Vasc Biol. 2005; 25: 1635-1640.
49. Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, Sabin
CA, Dhillon AP and Pepys MB. Transgenic human CRP is not pro-atherogenic, proatherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis. 2008; 196: 248255.
50. Ortiz MA, Campana GL, Woods JR, Boguslawski G, Soja MJ, Walker CL, and Labarrere
CA. Continuously-infused human C-reactive protein is neither proatherosclerotic nor
proinflammatory in apolipoprotein E-deficient mice. Exp Biol Med. 2009; 234: 624-631.
51. Paul A, Ko KWS, Li L, Yechoor V, McCroy MA, Szalai AJ, and Chan L. C-reactive
protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.
Circulation. 2004; 109: 647-655.
52. Schwedler SB, Amann K, Wernicke K, Krebs A, Nauck M, Wanner C, Potempa LA, and
Galle J. Native C-reactive protein increases whereas modified C-reactive protein reduces
atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2005; 112: 1016-1023.
53. Torzewski M, Reifenberg K, Cheng F, Wiese E, Küpper I, Crain J, Lackner KJ, and
Bhakdi S. No effect of C-reactive protein on early atherosclerosis development in LDLR/-

/human C-reactive protein transgenic mice. Thromb Haemost. 2008; 99: 196-201.

62

54. Singh SK, Thirumalai A, Hammond DJ Jr, Pangburn MK, Mishra VK, Johnson DA,
Rusiñol AE, and Agrawal A. Exposing a hidden functional site of C-reactive protein by
site-directed mutagenesis. J Biol Chem. 2012; 287: 3550-3558.
55. VanderLaan PA, Reardon CA, and Getz GS. Site specificity of atherosclerosis: Siteselective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol. 2004;
24: 12-22.
56. Goel R, Schrank BR, Arora S, Boylan B, Fleming B, Miura H, Newman PJ, Molthen RC,
and Newman DK. Site-specific effects of PECAM-1 on atherosclerosis in LDL receptordeficient mice. Arterioscler Thromb Vasc Biol. 2008; 28: 1996-2002.
57. King VL, Szilvassy SJ, and Daugherty A. Interleukin-4 deficiency decreases
atherosclerotic lesion formation in a site-specific manner in female LDL-receptor-/- mice.
Arterioscler Thromb Vasc Biol. 2002; 22: 456-461.
58. Schiller NK, Kubo N, Boisvert WA, and Curtiss LK. Effect of gamma-irradiation and
bone marrow transplantation on atherosclerosis in LDL receptor-deficient mice.
Arterioscler Thromb Vasc Biol. 2001; 21(10):1674-1680.
59. Babaev VR, Patel MB, Semenkovich CF, Fazio S, and Linton MF. Macrophage
lipoprotein lipase promotes foam cell formation and atherosclerosis in low density
lipoprotein receptor-deficient mice. J Biol Chem. 2000; 275(34): 26293-26299.
60. Obradovic MM, Trpkovic A, Bajic V, Soskic S, Jovanovic A, Stanimirovie J, Panic M,
and Isenovic ER. Interrelatedness between C-reactive protein and oxidized low-density
lipoprotein. Clin Chem Lab Med. 2015; 53: 29-34.

63

61. Moorkerja S, Francis J, Hunt D, Yong CY, and Nagpurkar A. Rat C-reactive protein
causes a charge modification of LDL and stimulates its degradation by macrophages.
Arterioscler Thromb Vasc Biol. 1994; 14: 282-287.
62. Krayem I, Bazzi S, and Karam M. The combination of CRP isoforms with oxLDL
decreases TNF-a and IL-6 release by U937-derived macrophages. Biomed Rep. 2017; 7:
272-276.
63. Rufail ML, Ramage SC, van Antwerpen R. C-reactive protein inhibits in vitro oxidation
of low-density lipoprotein. FEBS Lett. 2006; 580: 5155-5160.
64. Nayeri H, Naderi GA, Moghadam MS, Mohamadzadeh S, Boshtam M, Dinani NJ, and
Dehkordi AA. Effect of CRP on some of the in vitro physicochemical properties of LDL.
ARYA Atheroscler. 2010; 6: 85-89.
65. Eisenhardt SU, Starke J, Thiele JR, Murphy A, Stark GB, Bassler N, Sviridov D, Winkler
K, and Peter K. Pentameric CRP attenuates inflammatory effects of mmLDL by
inhibiting mmLDL-monocyte interactions. Atherosclerosis. 2012; 224: 384-393.
66. Chang M-K, Hartvigsen K, Ryu J, Kim Y, and Han KH. The pro-atherogenic effects of
macrophages are reduced upon formation of a complex between C-reactive protein and
lysophosphatidylcholine. J Inflamm. 2012; 9: 42.
67. Singh SK, Suresh MV, Prayther DC, Moorman JP, Rusiñol AE, and Agrawal A. CReactive Protein bound enzymatically modified low-density lipoprotein does not
transform macrophages into foam cells. J Immunol. 2008; 180(6):4316-4322.
68. Nunomura W, and Hatakeyama M. Binding of low density lipoprotein (LDL) to Creactive protein (CRP): A possible binding through apolipoprotein B in LDL at
phosphorylcholine-binding site of CRP. Hokkaido Igaku Zasshi. 1990; 65: 474-480.

64

69. Saxena U, Nagpurpkar A, Dolphin PJ, and Mookerjea S. A study on the selective binding
of apoprotein B- and E-containing human plasma lipoproteins to immobilized rat serum
phosphorylcholine-binding protein. J Biol Chem. 1987; 262: 3011-3016.
70. Taskinen S, Kovanen PT, Jarva H, Meri S, Pentikäinen MO. Binding of C-reactive
protein to modified low-density-lipoprotein particles: Identification of cholesterol as a
novel ligand for C-reactive protein. Biochem J. 2002; 367: 403-412.
71. Li H-Y, Wang J, Meng F, Jia Z-K, Su Y, Bai Q-F, Lv LL, Ma FR, Potempa LA, Yan YB,
Ji SR, and Wu Y. An intrinsically disordered motif mediates diverse actions of
monomeric C-reactive protein. J Biol Chem. 2016; 291: 8795-8804.

65

CHAPTER 3
Identical functions of native Limulus polyphemus C-reactive protein and structurally altered
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Abstract
C-reactive protein (CRP) has been conserved throughout evolution. Human native CRP exhibits
calcium-dependent binding specificity for phosphocholine. Human CRP in its non-native
structure expresses the capability to bind to deposited and conformationally-altered proteins,
which can be achieved by several means including treatment of CRP with acidic pH. The ligandbinding property of human CRP in its non-native structure has implications for toxic and
inflammatory conditions and favors the conservation of CRP throughout evolution. It is not
known, however, whether CRP from invertebrates exhibits structure-based ligand-binding
properties similar to that of human CRP. The aim of this study was to investigate the ligandbinding properties of CRP from American horseshoe crab Limulus polyphemus. We used
different protein ligands immobilized on microtiter plates as a model for deposited and
conformationally-altered proteins. We found that Limulus CRP binds to immobilized protein
ligands at physiological pH, in contrast to human CRP which requires acidic pH to do so. The
binding of Limulus CRP to these immobilized protein ligands occurred even in the absence of
calcium, suggesting that the binding was not mediated through exposed phosphocholine
molecules. We conclude that the structure-based ligand recognition function of CRP evolved
with the development of the immune system to expose a ligand-binding specificity only when
needed, that is, an inflammatory microenvironment would have to be sensed by CRP and that
CRP would change its structure to execute its function. Limulus CRP also provides us with a tool
to investigate the structure-function relationships of human CRP in animal models of
inflammation.
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Introduction
C-reactive protein (CRP), a member of the short pentraxin family, is a phylogenetically
conserved protein (1). From arthropods to humans, CRP has been found to be present in every
organism with similarity in three properties (2-6). First, structurally it is a cyclic oligomer of
almost identical subunits with subunit molecular weight ranging from 20-30 kDa. Second, it
recognizes and binds to phosphocholine (PCh) in a calcium-dependent manner and third, it
exhibits immunological cross-reactivity with human CRP. In humans, CRP is an acute phase
plasma protein but in some species it acts as a constitutive protein. CRP, from all species have an
amino acid sequence ranging from 206-218 amino acids, although the sequence homology
differs between species. Apart from human CRP, the function of CRP in other species is not
known (7).
Amongst all species, human CRP is the most studied protein in terms of structure and
function. CRP is a major acute phase hepatic protein in humans, the concentration of which
increases more than 1000-fold in acute inflammatory conditions (8). Structurally, human CRP is
a symmetrical pentamer consisting of five non-covalently attached subunits with an amino acid
sequence of 206 amino acids. It is a 120 kDa protein with subunit molecular weight of
approximately 23 kDa. Topologically, every subunit is folded into two anti-parallel beta sheets
depicting a jellyroll (9-10). Each subunit has a recognition face that consists of a PCh- binding
site with two coordinated calcium ions. PCh-binding site consists of Phe66, Thr76, and Glu81
along with residues 134-148 that forms the calcium ion binding site (11-14). The face opposite
to the recognition face is the effector face that has been shown to bind to C1q and activate
complement (15-17).
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In contrast to human CRP, CRP from the arthropod horseshoe crab (Limulus
polyphemus), is a constitutively expressed hepatopancreatic, glycosylated protein with a
concentration of approximately 1-7 mg/ml. It is the most abundant pentraxin followed by SAPlike pentraxin in the hemolymph (18-19). Structurally, it is a dodecamer consisting of two rings
of doubly stacked hexagons with an amino acid sequence of 218 amino acids. The molecular
weight of Limulus CRP is known to be approximately 300 kDa with subunit molecular weight
ranging between 25-30 kDa. It has been shown to be present in three different polymorphisms
with variable glycosylation (24-27). It has 25-30% sequence homology with human CRP along
with conserved protein structure of a jellyroll consisting of two anti-parallel beta sheets (20-26).
High resolution X-ray crystallographic studies revealed the structural similarity of the PChbinding site between Limulus and human CRP as Phe66, which is one of the amino acids
involved in forming the PCh-binding site in human CRP, is conserved in Limulus CRP. Residues
139-153 show sequence homology with residues 134-148 (calcium-ion binding site in human
CRP) in 9 out of 15 positions providing evidence for the conservation of the calcium ion binding
site (7,27).
It has been shown that human CRP, in its native conformation does not have the ability to
recognize and bind to immobilized, denatured and aggregated proteins. However, when exposed
to an acidic environment, the native pentameric structure transforms into another pentameric
configuration which further exposes a hidden ligand-binding site for non-PCh ligands. This
structural change enables CRP to bind to such aggregated proteins, thus providing a unique
structure dependent recognition feature to human CRP (28-30). However, it is not known if this
feature of human CRP has been conserved during evolution. Therefore, the aim of this study was
to investigate the structure-dependent ligand binding function of Limulus CRP. We found that
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CRP from an evolutionarily distant species, Limulus polyphemus, can recognize and bind to
immobilized, denatured and aggregated proteins in its native structural conformation. Therefore,
the ligand recognition feature is inherent in Limulus CRP, in contrast to human CRP.
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Materials and Methods
Purification of CRP from hemolymph of Limulus polyphemus
Limulus polyphemus hemolymph (blood; 50 ml) was centrifuged at 15000g for 15
minutes in order to pellet the cells yielding a clear blue plasma. Limulus plasma was then
subjected to Sepharose 4B absorption for the removal of carbohydrate binding proteins.
Approximately 10 ml Sepharose 4B beads (Sigma Aldrich; cat# 4B200) were packed in a
column and equilibrated with 10 ml of TBS (10 mM Tris + 150 mM NaCl; pH 7.2) + 2 mM
CaCl2. Limulus plasma was then passed through packed Sepharose 4B beads and the plasma was
collected. The column was washed with TBS + 2 mM CaCl2 until the blue color disappeared
from the beads (approximately 10 ml of TBS + 2 mM Ca2+). The plasma was further subjected to
polyethylene glycol (PEG) treatment for the removal of hemocyanin by adding 3% of PEG 8000
to the plasma. The treatment with PEG 8000 was carried out on a shaker for 16 hours at 40C.
Following PEG treatment, plasma was centrifuged at 30000g for 30 minutes and the dark blue
pellet was discarded leaving a clear, transparent plasma. CRP was isolated from the plasma of
Limulus polyphemus in a series of three chromatography that included affinity chromatography,
anion exchange chromatography and HPLC (Gel filtration protein purification system).
PCh affinity chromatography was performed for purifying PCh-binding Limulus CRP
(CRP-I), using commercially available PCh-conjugated Sepharose beads (Pierce), as described
previously (31). Briefly, 1ml PCh-Sepharose beads were packed into a column and equilibrated
with 10 ml of BBS (0.1M borate-buffered saline; pH 8.3) +3 mM CaCl2 [BBS-Ca]. The clear,
transparent Limulus plasma obtained after Sepharose absorption, high speed centrifugation and
PEG treatment was diluted 1:3 with BBS-Ca and passed through the column at a slow flow rate.
The flow-through from the column was collected and saved to purify further Limulus protein still
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present in the hemolymph. The column was washed with BBS-Ca and CRP was eluted from the
column by passing BBS + 5 mM EDTA (BBS-EDTA). 0.5 ml fractions were collected and
A280 for each fraction was measured. Fractions were collected until the A280 < 0.02. After all
bound CRP was eluted, fractions containing CRP were pooled and dialyzed against TBS + 2 mM
CaCl2. PEt-binding Limulus CRP (CRP-II) was purified using phosphoethanolamine (PEt)
affinity chromatography, as described previously (31). Briefly, 1ml PEt conjugated Sepharose
beads were packed into a column and equilibrated with 10 ml of BBS-Ca. PEt binding protein
was purified from PEt-Sepharose column in the manner similar to the one described above for
purification using PCh-Sepharose column. After purification, CRP-containing fractions were
dialyzed against TBS + 2 mM CaCl2 and both PCh-binding Limulus CRP (CRP-PCh) and PEtbinding Limulus CRP (CRP-PEt) were processed for gel filtration chromatography.
Gel filtration chromatography was performed using Superose 12 (10/300 GL Pharmacia)
column connected to the BioRad's Biologic Duo Flow Protein Purification System, as described
previously (31). Briefly, the column was equilibrated with 20 ml of filter-sterilized and degassed
TBS + 5 mM EDTA at a flow rate of 0.3 ml/min. Concentrated CRP (400 μl) was injected into
the Superose12 column using a loop and CRP was eluted with TBS + 5 mM EDTA. Fractions
(0.25 ml) were collected and A280 measured to determine the elution volume of CRP from the
column. CRP-containing fractions were pooled and dialyzed against TBS+2mM CaCl2.
Molecular weight determination of Limulus CRP by Gel filtration calibration
In order to elucidate molecular weight of Limulus CRP (CRP-I and CRP-II), we
performed gel filtration chromatography, as described above, of three known molecular weight
proteins [Apoferritin (440 kDa), human CRP (120 kDa) and BSA (66 kDa)]. Limulus CRP (both
PCh and PEt binding protein) were then subjected to gel filtration purification. Apoferritin,
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human CRP and BSA were eluted from the column using TBS + 2 mM CaCl2 while Limulus
CRP was purified using TBS + 5 mM EDTA. A280 of the fractions was measured and the elution
volume of the protein was determined by the area of the single peak obtained in the purification
profile. Log molecular weight of the proteins were plotted against elution volume (ml) and based
on the molecular weight of the standard proteins, the molecular weight of Limulus CRP species
was determined.
SDS PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis)
In order to determine purity of Limulus CRP (both CRP-I and CRP-II), a denaturing, 420% gradient gel electrophoresis was performed. A 4-20% resolving gel (30% acrylamide +
1.5M Tris HCl pH 8.8+ 10% SDS + Glycerol + TEMED + 10% APS+ H20) was prepared using
a gradient mixer and following its polymerization, 4% stacking gel (30% acrylamide + 0.5M Tris
HCl pH 6.8+ 10% SDS + TEMED + 10% APS+ H20) was added and allowed to polymerize.
Protein (10 µg) diluted with 4X sample loading buffer (1M Tris HCl pH 6.8 + 40% glycerol +
SDS +0.5% Bromophenol blue +b-mercaptoethanol) was loaded and 1X running buffer (3g Tris
base + 14.4g Glycine + 1g SDS+ H20) was added to the tank. Gel was subjected to
electrophoresis at 80 volts until protein enters the resolving gel and then, at 150 volts for 5 hours.
Following electrophoresis, the gel was stained in Coomassie staining solution (45% methanol +
0.25% Coomassie brilliant blue G250 + 7.5% glacial acetic acid + H20) overnight at room
temperature and destained (45% methanol + 7.5% glacial acetic acid) until the background was
clear and the and the bands were visible.
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Anti-Limulus CRP
Rabbit polyclonal antibodies to preferred Limulus CRP-I were generated commercially
(Thermofischer). In order to evaluate the binding avidity of anti- Limulus CRP for CRP-I and its
cross reactivity with CRP-II, ELISA was performed. Briefly, microtiter wells (96 well plate)
were coated with CRP-I and CRP-II (10 μg/ml-0; two fold serial dilution) and incubated at 370 C
for 2 hours. The wells were then blocked with TBS containing 0.5% gelatin (Sigma-Aldrich) for
45 minutes at room temperature. After washing with TBS-Ca (TBS containing 2 mM CaCl2,
0.1% gelatin, and 0.02% Tween 20), rabbit anti- Limulus CRP Ab, diluted in TBS-Ca (1:500
dilution), was added to the well and incubated for 1 hour to detect bound CRP. HRP-conjugated
donkey anti-rabbit IgG, diluted in TBS-Ca (1:1000 dilution), was used as the secondary
antibody. Color was developed using ABTS as the substrate and the A value was read at 405 nm
using a microplate spectrophotometer.
Amino acid sequencing
Amino acid sequencing of gel filtration purified Limulus CRP (CRP-I and CRP-II) was
performed by the Molecular Structure Facility, University of California, Davis.
Protein Ligand Binding Assay
The protein ligand binding assay was used to determine the binding of Limulus CRP
(CRP-I and CRP-II) to a variety of immobilized proteins. Factor H (Complement Technology;
cat# A137), IgG (Sigma-Aldrich; cat # I2511), BSA (Sigma-Aldrich; cat# 05470), amyloid β
peptide 1–42 (Ab) (Bachem; cat# 4014447), Ac-LDL (acetylated LDL), ox-LDL (oxidized
LDL), and gelatin (Sigma-Aldrich; cat# G6650) were used as protein ligands. Ac-LDL and oxLDL were prepared as described previously (28). Microtiter wells were coated with 10 μg/ml
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protein ligands diluted in TBS (100 μl/well) and incubated overnight at 4 °C. The unreacted sites
in the wells were blocked with TBS containing 0.5% gelatin. Limulus CRP I (20 μg/ml-0; two
fold serial dilution) and Limulus CRP II (40 μg/ml-0; two fold serial dilution) were diluted in
TBS-Ca (presence of calcium) or TBS-EDTA (TBS containing 5 mM EDTA, 0.1% gelatin, and
0.02% Tween 20; absence of calcium), added to the wells, and incubated overnight at 4 °C. The
wells were then washed with the appropriate buffers, TBS-Ca (presence of calcium) or TBSEDTA (absence of calcium) prior to the addition of anti- Limulus CRP Ab, diluted in TBS-Ca
(1:500 dilution) was used to detect bound CRP. After 1 hour, incubation at 37 °C, the wells were
rinsed again and HRP-conjugated donkey anti-rabbit IgG (GE Healthcare) diluted in TBS-Ca
was added for 1 h at 37 °C. Color was developed using ABTS as the HRP substrate, and
the absorbance was read at 405 nm using a microplate reading spectrophotometer.
Deglycosylation of Limulus CRP
Deglycosylation of CRP-I and CRP-II was performed using chemical and enzymatic
methodolgy. Chemical deglycosylation was performed using trifluoromethanesulfonic acid
(TFMS) (Sigma; cat# 34,781-7) and methodology was followed according to manufacturer’s
instructions for Glycoprofile IV chemical deglycosylation kit (Sigma; cat # PP0510). Briefly,
150 µl of chilled TFMS was added to 1 mg of pre-cooled lyophilized Limulus CRP samples and
incubated for 25 minutes on ice with occasional shaking. Bromophenol blue solution (0.2%; 4
µl) was added to the reaction followed by dropwise addition of 60% pyridine solution (Sigma;
cat# P 5496) in a methanol-dry ice bath until the color of the reaction changes from red to light
purple or blue. The deglycosylated samples (CRP-I and CRP-II) were dialyzed against 1x TBS
overnight with four changes of buffer.
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Enzymatic deglycosylation was performed under denaturing and non-denaturing
conditions using a protein deglycosylation mix II kit (New England Biolabs, cat# P6044)
according to manufacturer’s instructions. Following deglycosylation, the protein samples were
dialyzed against TBS for 16 hours at 40C with two changes of buffer. Deglycosylated proteins
were then subjected to SDS PAGE. The binding activity of deglycosylated Limulus CRP species
(CRP-I and CRP-II) to immobilized protein ligands at physiological pH was evaluated by an
ELISA-based assay using Ab was used as the representative protein ligand.
Data Plotting
All experiments were performed three times, and comparable results were obtained each
time. The results of a representative experiment are shown in the figures where the raw data
(A405) were used to plot the curves.
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Results
Two CRP species with varying affinities for PCh and PEt were isolated from the
hemolymph of Limulus polyphemus. The gel filtration elution profiles of both CRP- I (PChbinding protein) and CRP- II (PEt-binding protein) were similar as both proteins eluted as a
single peak at the same elution volume and the molecular weight was estimated to be
approximately 300 kDa (Fig 3.1 A and B). Denaturing SDS PAGE analysis of CRP- I and CRPII revealed two bands of molecular mass 29.5 kDa and 26.9 kDa respectively (Fig 3.1 C).
Although, both CRP-I and CRP-II contained two bands but, the intensity of the bands differed
between the two species, with the 26.9 kDa band having similar intensity for both CRP-I and
CRP-II while the intensity of the 29.5 kDa band was more prominent for CRP-I as compared to
CRP-II. Another difference between CRP-I and CRP-II was observed during affinity purification
where CRP-I, eluted either by EDTA or PCh, produced identical bands on denaturing SDSPAGE gels while CRP-II eluted by EDTA, contained an additional band (32.3 kDa) that was not
observed by PEt elution.
The molecular weight of the protein as determined by gel filtration profile and the
molecular mass of the subunits for both CRP-I and CRP-II, suggests that it is composed of 12
subunits, six copies of each subunit stacked together as an oligomer. This result is consistent
with a previously published study that states the determined molecular weight and subunit
composition of Limulus CRP (25). Because Limulus CRP is a glycoprotein, the differential
purification and the intensity of the subunits between CRP-I and CRP-II may be attributed to the
differential glycosylation patterns on the two CRP species. When the binding affinity for
antibody (rabbit polyclonal anti-CRP-I) was analyzed for CRP-I and CRP-II, we found that
rabbit polyclonal anti-CRP-I binds to CRP-II with similar affinity as it does to CRP-I (Fig 3.1
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D). Further, purified CRP-I and CRP-II were subjected to amino acid sequencing. The amino
acid sequence of first ten amino acids of CRP-I was LEEGEITSKV and CRP-II was
LEEGEITSKI. The amino acid sequence of CRP-I and CRP-II was similar for the first nine
residues. However, it differed at the tenth residue. Evidence of polymorphism for Limulus CRP
has been reported, where the amino acid sequence of the different isoforms of Limulus CRP were
identical except at certain amino acid positions (23).
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Figure 3.1: Purification and characterization of CRP-I and CRP-II. (A) Gel filtration
elution profiles of of CRP-I (red) and CRP-II (black) purified from the hemolymph of
Limulus polyphemus are shown. Molecular weight of CRP-I and CRP-II was determined
by using gel filtration elution profiles of Apoferritin (440 kDa), human CRP (120 kDa),
and BSA (66 kDa). Chromatography was performed in TBS, pH 7.2, containing 5 mM
EDTA. A representative of three chromatograms from the Superose 12 gel filtration
column is shown. (B) Molecular weight of Limulus CRP-I and CRP-II was determined to
be 300 kDa. A linear regression plot of (A) is shown, where the molecular weight of
standards are plotted against their gel filtration elution volume. Limulus CRP-I and CRPII (red), based on their gel filtration elution volume, are extrapolated and their molecular
weight determined. (C) Coomassie blue-stained SDS-PAGE comparing the pattern of
proteins present in Limulus CRP purified by either phosphocholine (PCh) or
phosphoethanolamine (PEt). CRP-I and CRP-II (10 μg) were electrophoresed on a 4–
20% gradient SDS-PAGE gel under denaturing conditions Lanes 1 and 6, molecular
weight standards. Lanes 2 and 3, CRP-I eluted by EDTA and PCh respectively. Lanes 4
and 5, CRP-II eluted by EDTA and PEt respectively. (D) Rabbit polyclonal antibody to
CRP-I displays cross- reactivity with CRP-II. Enzyme-linked immunosorbent assay
(ELISA) plates were coated with increasing amounts CRP-I and CRP-II, as indicated.
The binding of anti-CRP-I antibody was detected using HRP-conjugated donkey antirabbit IgG, a colorimetric substrate, and quantified by measuring the absorbance at 405
nm using a microplate reading spectrophotometer.
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The binding of CRP-I and CRP-II to a variety of immobilized protein ligands, such as
Ab, ox-LDL, Ac-LDL, Factor-H, aggregated IgG (agg IgG), BSA, and gelatin was investigated
at physiological pH. All ligands were used at a concentration of 10 μg/ml to coat the wells. As
shown (Fig 3.2 A), CRP-I bound to these immobilized protein ligands in a concentrationdependent manner, in the following order Aβ > Ac-LDL > ox-LDL > agg-IgG > Factor-H. We
did not detect binding of CRP-I to either BSA or gelatin. We next sought to determine if calcium
binding site is critical for CRP-I to recognize and bind to these immobilized ligands by
performing the experiment in the presence of EDTA (absence of calcium). As shown (Fig 3.2 B),
the binding curves of CRP-I binding to immobilized ligands are similar to the ones observed
above, in the presence of calcium (Fig 3.2 A).
When the binding of CRP-II to immobilized protein ligands was analyzed at
physiological pH, similar results were obtained as for CRP -I, where CRP-II bound to these
immobilized protein ligands in a concentration-dependent manner, in the following order Aβ >
ox-LDL > Ac-LDL > agg-IgG > Factor-H while no binding was observed to either BSA or
gelatin (Fig 3.2 C). Also, the binding of CRP-II to immobilized protein ligands was also calcium
independent as it recognized and bound to these immobilized ligands in the absence of calcium
(Fig 3.2 D). The manner in which CRP-II bound to these immobilized ligands, in the absence of
calcium was similar as observed in the presence of calcium with the exception of Ac-LDL and
ox-LDL ( Ac-LDL > ox-LDL). Because both Ac-LDL and ox-LDL are modified versions of
lipoproteins, the differential binding in the absence of calcium does not correlate with the change
in binding specificities of CRP-II.
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Figure 3.2: Limulus CRP-I and CRP-II recognizes and binds to immobilized protein
ligands at physiological pH. (A and C) For analyzing binding of CRP-I (A) and CRP-II
(C) to immobilized ligands, microtiter wells were coated with 10 μg/ml of amyloid β
peptide 1–42 (Ab), ox-LDL, ac-LDL, factor H, aggregated IgG (agg IgG), BSA, and
gelatin. Increasing concentration of CRP-I (0-20 μg/ml) and CRP-II (0-40 μg/ml) diluted
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in TBS-Ca were then added to the wells and incubated for 2 hours at 37 °C. Bound CRP
was detected by using rabbit anti-CRP-I antibody and HRP-conjugated donkey anti-rabbit
IgG. Color was developed, and the A value was read at 405 nm. A representative of three
experiments is shown. (B and D) Representative result for the binding of CRP-I (B) and
CRP-II (C) to the above mentioned immobilized ligands, in the absence of calcium (TBSEDTA), are shown.

These data indicate that both CRP-I and CRP-II have the ability to recognize
immobilized and conformationally altered, denatured, and aggregated proteins at physiological
pH. Also, these proteins might be recognizing and binding to amyloid-like like structures that are
exposed by the protein ligands upon immobilization (30) because as the extent of the exposure of
these amyloid-like structures after immobilization decreases (Aβ < ox-LDL < Ac-LDL < agg
IgG < Factor-H < BSA < gelatin), the ability of CRP-I and CRP-II to recognize them and bind to
them also decreases. Also, this binding is calcium independent and calcium binding site doesn’t
play a role in recognition of conformationally altered, denatured, and aggregated proteins by
CRP-I and CRP-II.
Both species of Limulus CRP, CRP-I and CRP-II, are glycosylated proteins, unlike
human CRP (25, 26). In order to investigate the role of carbohydrate moieties present on CRP-I
and CRP-II, we subjected both proteins to chemical and enzymatic deglycosylation. Denaturing
SDS PAGE analysis of CRP-I following enzymatic deglycosylation (deglycosylation performed
under denaturing and non-denaturing conditions), revealed no alteration in the mobility of either
of the two bands. However, when CRP-I was subjected to chemical deglycosylation, only one
band of molecular mass 23.2 kDa was observed (Fig 3.3 A). In comparison, enzymatic
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deglycosylation of CRP-II, altered (reduced) the intensity of the 29.5 kDa band. Chemical
deglycosylation of CRP-II affected the mobility of the observed three bands resulting in two
bands of molecular mass 26 kDa and 23.2 kDa, respectively (Fig 3.3 C). Although, three bands
were observed in denaturing SDS-PAGE analysis of native CRP-II, anti-CRP-I antibody
recognized only two bands of molecular mass 29.5 kDa and 26.9 kDa, respectively (data not
shown). Thus, the deglycosylated band of 26 kDa observed post chemical deglycosylation of
CRP-II could either be a deglycoylsylated product of the non-specific 32.3 kDa band or could be
a result of partial deglycosylation. While we could fully deglycosylate CRP-I and CRP-II, it
could not be evaluated in functional assays since deglycosylation by chemical and enzymatic
(under denaturing conditions) methodology rendered the protein in a non-native state (confirmed
by ELISA; data not shown).
Although, enzymatic deglycosylation (performed under non-denaturing conditions), did
not produce a shift in the mobility of CRP-I and CRP-II bands in a denaturing SDS-PAGE, we
wanted to determine any differences in the functional binding between native and deglycosyated
state of Limulus CRP species. Because there lies a possibility that the protein was partially
deglycosyated but there was no noticeable change in the SDS-PAGE band pattern. This might be
explained in lieu of the extent of glycosylation on these proteins, as they are not fully known.
Therefore, we compared the functional binding activity of native and deglycosylated CRP-I and
CRP-II to an immobilized protein ligand, Aβ. As shown (Fig 3.3 B), native CRP-I bound to Aβ
in a CRP concentration dependent manner. However, enzymatically deglycosylated CRP-I bound
to Aβ with approximately 100-fold less avidity when compared to native CRP-I. Similar results
were observed for CRP-II (Fig 3.3 D).
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Figure 3.3: Deglycosylation of CRP-I and CRP-II reduces binding to immobilized
amyloid β peptide 1–42: (A) CRP-I was deglycosylated using chemical, enzymatic
(under denaturing), and enzymatic (under non- denaturing) means. Native CRP-I (10 μg)
and deglycosylated CRP-I (10 μg) were subjected to SDS-PAGE under reducing
conditions in a 4–20% gradient gel. A representative Coomassie Blue-stained gel is
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shown; lane 1: molecular weight marker, lane 2: Native CRP-I, lane 3: Chemically
deglycosylated CRP-I, lane 4: Enzymatically (under denaturing conditions)
deglycosylated CRP-I, and lane 5: Enzymatically (under non-denaturing conditions)
deglycosylated CRP-I. (B) Microtiter wells were coated with amyloid β peptide 1–42 (10
μg/ml). The unreacted sites in the wells were blocked with gelatin. Native CRP-I (black)
and enzymatically (under non-denaturing conditions) deglycosylated CRP-I (red) (both;
0-40 μg/ml) diluted in TBS-Ca were added to the wells and incubated for 2 hours at 37
°C. Bound CRP was detected by using rabbit anti-CRP-I antibody and HRP-conjugated
donkey anti-rabbit IgG. Color was developed, and the A value was read at 405 nm. A
representative of three experiments is shown. (C) CRP-II was deglycosylated using
chemical, enzymatic (under denaturing), and enzymatic (under non- denaturing) means.
Native CRP-II (10 μg) and deglycosylated CRP-II (10 μg) were subjected to SDS-PAGE
under reducing conditions in a 4–20% gradient gel. A representative Coomassie Bluestained gel is shown; lane 1: Native CRP-II, lane 2: Chemically deglycosylated CRP-II,
lane 3: enzymatically (under denaturing conditions) deglycosylated CRP-II, lane 4:
enzymatically (under non-denaturing conditions) deglycosylated CRP-II, and lane 5:
molecular weight marker. (D) Microtiter wells were coated with amyloid β peptide 1–42
(10 μg/ml). The unreacted sites in the wells were blocked with gelatin. Native CRP-II
(black) and enzymatically (under non-denaturing conditions) deglycosylated CRP-II (red)
(both; 0-40 μg/ml) diluted in TBS-Ca were added to the wells and incubated for 2 hours
at 37 °C. Bound CRP was detected by using rabbit anti-CRP-I antibody and HRPconjugated donkey anti-rabbit IgG. Color was developed, and the A value was read at 405
nm. A representative of three experiments is shown.
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These data indicated that the presence of carbohydrate moieties on CRP-I and CRP-II
plays a role in its ability to recognize and bind to conformationally altered, denatured, and
aggregated proteins since, removal of these moieties leads to loss of these protein’s ability to
recognize immobilized proteins.
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Discussion
A SAP-like pentraxin has been shown to be present in the hemolymph of Limulus
polyphemus along with CRP (34). As opposed to Limulus CRP which has an affinity for PCh and
PEt, Limulus SAP-like pentraxin has an affinity for PEt and carbohydrate moieties but not PCh.
Therefore, we pre-absorbed the SAP-like pentraxins from hemolymph by using Sepharoseaffinity chromatography prior to purifying CRP. We then purified CRP by two means, PCh
dependent affinity chromatography and PEt dependent affinity chromatography and investigated
the ligand recognition function of Limulus CRP. Our major findings were as follows: 1) Limulus
CRP is a 300 kDa protein that exists as a dodecamer with two rings of six subunits each, as
published previously (25); 2) The differential glycosylation patterns on Limulus CRP might be
playing a role in its differential affinity for PCh and PEt; 3) Limulus CRP can recognize and bind
to immobilized, denatured, and aggregated proteins in a calcium independent manner, at
physiological pH; and 4) The ligand recognition function of Limulus CRP is dependent on its
carbohydrate moieties since partial enzymatic deglycosylation greatly affected its ligand binding
properties.
American horseshoe crab, Limulus polyphemus, is an evolutionarily distant species the
origin of which dates back to 300-500 million years. Amongst the entire taxa of arthropods, this
is the only species in which CRP along with other pentraxins has been identified as the vertebrate
pentraxins counterpart (18). Along with hemocyanin and a2- macroglobulin, pentraxins are the
third most abundant proteins present in the hemolymph of these arthropods (34-35). The two
major pentraxins are CRP (constituting about 80% of pentraxin population) and SAP-like
pentraxins (constituting about 8-19% of pentraxin population). The N-terminal amino acid
sequence differs significantly between CRP and SAP-like pentraxin along with the affinity for
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ligands. CRP has an affinity for PCh and PEt but not carbohydrate moieties while SAP-like
pentraxins has an affinity for PEt and carbohydrate moieties but not PCh (18-19). A third
pentraxin, limulin (approximately 1% of pentraxin population), was also identified in the
hemolymph of these animals. Initially, limulin and Limulus CRP were considered to be the same
because of identical N terminal amino acid sequence. However, it was later on shown that
though closely related, the two proteins are unique with differences in their ligand affinity. CRP
has an affinity for PCh and PEt but not sialic acid while limulin has an affinity for PCh, PEt, and
sialic acid (20-21, 37-40). In our study, we purified two different isoforms of Limulus CRP with
differences in their ligand affinity for PCh and PEt. Since, our protein of interest was CRP,
passage of hemolymph over Sepharose column eliminated SAP-like pentraxin. Also, neither of
the two isoforms of Limulus CRP, CRP-I and CRP-II are likely to be limulin because when both
CRP isoforms were passed over fetuin-sepharose column (sialic acid affinity chromatography),
none of them bound to the column (data not shown).
CRP is present in the hemolymph of Limulus polyphemus in a wide concentration range
of 0.2-6 mg/ml (25). We purified CRP-I at a concentration of 0.2 mg/ml and CRP-II at a
concentration of 0.006 mg/ml. We observed that the affinity of Limulus CRP for PCh-sepharose
is about 5 mg/ml beads in contrast to human CRP whose affinity is over 10 mg/ml beads which
is consistent with a previously reported study (37). In contrast, the affinity of Limulus CRP for
PEt-sepharose is about 2 mg/ml beads, which is consistent with the behavior of human CRP as
human CRP has much higher affinity for PCh-sepharose as compared to PEt-sepharose (25). The
lower affinity of Limulus CRP for PCh-sepharose in comparison to human CRP could be
attributed to its higher molecular weight that can limit its access to the PCh moieties when
complexed with Sepharose. Limulus CRP, purified by PCh affinity chromatography (CRP-I) and
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PEt affinity chromatography (CRP-II), is a high molecular weight protein with estimated
molecular weight of 300 kDa organized as double stacked, identical hexameric assembly
(dodecamer) (22-23). Each subunit molecular mass was estimated as 26-32 kDa. As opposed to
human CRP that exists in mammalian circulation as a non-glycosylated protein, Limulus CRP
has been known to exist in three different polymorphisms with differences attributed to the
glycosylation pattern as these three polymorphisms share similar amino acid sequencing with
only 10 % microheterogeniety amongst them (23-27). The N terminal amino acid sequencing of
CRP-I and CRP-II were similar (Leu-Glu-Glu-Gly-Glu-Gly-Ile-Thr-Ser-Lys-Val), suggesting
that the differential glycosylation of the two CRP’s contributes to their variable affinity for PCh
and PEt. Limulus CRP subunits are glycosylated by a single oligosaccharide chain of
composition Man2GlcNAc2 (differential glycosylations of Man3GlcNAc2, Man4GlcNAc2, or
Man5GlcNAc2) (26). The difference in the mannose chains in the CRP subunits gives differential
intensity to the bands in SDS PAGE for CRP-I and CRP-II (two bands of molecular mass 26.9
kDa and 29.5)
Human CRP has been shown to be present in two structural configurations: a native
pentameric CRP at physiological pH that does not recognize immobilized, denatured and
aggregated proteins and a non-native pentameric CRP at acidic pH that can recognize and bind to
immobilized, denatured and aggregated proteins (29). In order to determine if this structurebased ligand binding property of human CRP is inherent in Limulus CRP, we performed ligand
binding assays. We found that unlike human CRP, Limulus CRP in its native structural
configuration at physiological pH can recognize and bind to immobilized, denatured and
aggregated proteins. Both CRP-I and CRP-II does not need any structural modification to gain
the ligand binding property of non-native pentameric human CRP. However, upon exposure to
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an acidic environment, both CRP-I and CRP-II recognized and bound to immobilized, denatured
and aggregated proteins more efficiently than it did at physiological pH (data not shown). The
functional ligand binding ability of CRP-I and CRP-II at both physiological and acidic pH might
provide protection against enhanced protein toxicity in these arthropods, as they are constantly
being exposed to harsh environments. Non-native human CRP has an exposed ligand binding site
that can recognize and bind non-PCh containing ligands (immobilized, denatured and aggregated
proteins) in a calcium-independent manner. This property of non-native human CRP is consistent
with native Limulus CRP, as it also recognizes and binds to immobilized ligands in the presence
and absence of calcium. This ligand binding property of Limulus CRP in the absence of calcium
further suggests that it does not bind to the PCh moieties , if exposed, on these ligands as
presence of calcium is critical for PCh-binding. The pattern of CRP-I and CRP-II binding to
immobilized ligands suggests that it recognizes and bind to amyloidogenic-like structures
expressed by the proteins upon immobilization as it binds more efficiently to Ab compared to
factor-H and doesn’t bind at all to BSA and gelatin.
Over the course of evolution, the glycosylation patterns on CRP have changed, where
Limulus CRP-I and CRP-II are glycosylated while human CRP is non-glycosylated. Human CRP
does possess sites of glycosylation but they are hidden in its native conformation and therefore
may provide no functional advantage to native CRP (41-43). In order to determine if the
glycosylated moieties have any role in the structure-ligand function of Limulus CRP, we deglycosylated CRP-I and CRP-II and observed that the ability of the deglycosylated CRP-I and
CRP-II, to recognize and bind to immobilized, denatured and aggregated proteins was greatly
decreased (approximately 100 fold) when compared to their glycosylated counterparts.
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Therefore, native glycosylated Limulus CRP displays similar ligand binding function as nonnative human pentameric CRP.
An innate immune system has a pivotal role in host-defense mechanism where its major
function is identification of pathogens and its clearance or inactivation. The innate immune
system is unique in these arthropods as they have complement-like activity but without the
acquired immunoglobulin‐dependent immunity that is present in vertebrates. Hence, the immune
system evolved from these ancient species, where a2- macroglobulin and pentraxins exhibit the
function of immune defense proteins using cytolysis for pathogen elimination, to humans where
this function is taken over by acute phase reactants and complement activation (18). As the
immune system evolved, the nature of CRP gene expression also evolved from a constitutively
expressed protein in Limulus polyphemus to an acute phase protein in humans.
We conclude that though the ligand-binding properties of Limulus CRP are not identical
to that of native human CRP, they overlap the ligand-binding properties of non-native
pentameric human CRP that can be generated at inflammatory microenvironments. Also,
changing the glycosylation state of Limulus CRP, changes its ligand-binding and overlapping
with native human CRP. This suggests that CRP evolved as a component of and along with the
development of the entire immune system.
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PCh-binding Limulus CRP
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PEt-binding Limulus CRP
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Amyloid b peptide 1-42

Ox-LDL

Oxidized low-density lipoprotein

Ac-LDL

Acetylated low-density lipoprotein

TFMS

Trifluoromethanesulfonicacid

TBS-Ca

TBS, pH 7.2, containing 0.1% gelatin, 0.02% Tween 20 and 2 mM CaCl2

TBS-EDTA

TBS, pH 7.2, containing 0.1% gelatin, 0.02% Tween 20 and 5 mM EDTA
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Abstract
Gene expression regulation of C-reactive protein (CRP) occurs at transcriptional level by various
cytokine inducible and constitutively active transcription factors. IL-6 is the major cytokine that
is known to induce CRP expression by activation of transcription factors STAT3 and C/EBPb.
The proximal 157 bp region of the CRP promoter has been shown to be sufficient to induce CRP
transcription in response to IL-6 and binding sites for both these transcription factors are present
within the -157 bp region of CRP promoter. It has been previously reported that the proximal
300 bp region of the CRP promoter elicits a higher IL-6 response compared to the 157 bp region.
An additional C/EBPb site has been shown to be present at position -222, but additional binding
sites for STAT3 have not been located between -157 to -300 bp region. In the current study, we
discovered multiple putative IL-6 inducible STAT3 binding sites, located at position -72, -134,
and -165 respectively, in addition to the previously reported transcriptionally active STAT3 site
at -108. We found that, although STAT3 binds to its cognate site at positions -134 and -165, the
STAT3 binding site at -134 is transcriptionally active, unlike -165. The STAT3 site at position 134 does not activate CRP transcription but rather regulates the gene expression of CRP. We
hypothesize that IL-6 inducible STAT3 binding sites at position -134 and -108 act co-operatively
with each other to activate CRP transcription wherein STAT3 (-134) regulates a crosstalk
mechanism between STAT3 (-108) and other transcription factors.
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Introduction
C-reactive protein (CRP) is an acute phase protein of the innate immune response of
humans, serum concentration of which increases significantly followed by either a chronic or an
acute inflammatory insult (1-6). It is a multifunctional, host defense protein that is produced by
hepatocytes (7,8). The regulation of CRP synthesis occurs at transcriptional level wherein
cytokines such as interleukin 6 (IL-6) and interleukin 1b (IL-1b) induce CRP expression via
activation of various transcription factors (9,10). IL-6, alone or in synergy with IL-1b, actuates
CRP transcription by activating C/EBP (CCAAT/enhancer-binding protein) family of
transcription factors and STAT (signal transducers and activators of transcription) family
members. IL-1b alone does not activate CRP transcription but it does so in synergy with IL-6 via
activation of nuclear factor kappaB (NF-kB) (8, 11-17). Cytokine (IL-6 + IL-1b)-induced CRP
transcription has been observed in human hepatoma cell line Hep3B while IL-6 activated
transcription factors have been shown to induce CRP expression in other hepatic cell lines as
well (11, 14-16, 18).
The proximal 157 bp region of the CRP promoter (-157/+1) has been shown to be
sufficient for inducing CRP transcription in response to IL-6 as IL-6 activated transcription
factors such as C/EBPb and STAT3 have binding sites on the CRP promoter, centered at position
-52 and -108, respectively (9,13). Also, IL-1b activated transcription factor, NF-kB binds to its
site located at position -69 on CRP promoter (Fig 1A). NF-kB regulates CRP transcription via
formation of homodimers or heterodimers of five NF-kB proteins namely p50, p52, p65, c-Rel,
and c-Rel B (8). In addition to the cytokine activated transcription factors, other constitutively
active transcription factors such as C/EBPz, RBP-Jk, Oct-1, HNF-1, and HNF-3 have been
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shown to regulate CRP gene expression (7,12,19).
STAT3, one of the STAT family members, transitions from a non-active cytoplasmic
non-phosphorylated monomeric state to an active nuclear tyrosine-phosphorylated dimeric state.
This transition is initiated by IL-6 binding to its receptor complex that initiates a pathway of
Janus kinase kinases phosphorylation with subsequent phosphorylation, dimerization, and
nuclear translocation of STAT3 (20,21). STAT3 has been shown to bind to acute phase response
elements on the promoter regions containing TT(N)4AA or TT(N)5AA motifs specifically (2224). One such IL-6 induced STAT3 response element, centered at position -108 on the proximal
human CRP promoter containing the sequence TTCCCGAA, has been shown to induce CRP
transcription (13).
It has been previously reported that the proximal 300 bp region of the CRP promoter (300/+3) elicits a higher IL-6 response when compared to the 157 bp region. In addition to the IL6 induced transcriptionally active C/EBPb site positioned at -52, another C/EBPb site has been
shown to be present at position -222. However, additional binding sites for STAT3 are not
known between -157 bp to -300 bp region. In the current study, the aim was to locate putative
IL-6 responsive STAT3 binding sites in the -300 bp region of CRP promoter and if located,
determine whether these sites are transcriptionally active. We revisited the -300/+3 region of
CRP promoter and found three additional, putative STAT3 binding sites centered at position -72,
-134, - 165 along with the previously reported STAT3 site at position -108. Our data indicates
that, in addition to the STAT3 site at position -108, STAT3 binds to IL-6 responsive STAT3
binding sites located at position -134 and -165, but only the STAT3 site at -134 is
transcriptionally active. Also, STAT3 site at -134 does not activate CRP transcription but rather
regulates CRP expression via facilitating crosstalk between other transcription factors.
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Experimental Procedures
Identification of putative STAT3-binding sites in -300 bp region of the CRP promoter
Putative STAT3- binding sites were identified by visual inspection of the proximal 300
bp region of the CRP promoter. TT(N)4AA or TT(N)5AA containing motifs were considered
potemtial STAT3-binding regions.
Preparation of Nuclear Extract and EMSA (Electrophoretic mobility gel shift assay)
Hep3B cells were used as the source of nuclear extracts. Cells were cultured in a 100 mm
dish using RPMI media (containing 10% FBS and 1% Penicillin-Streptomycin stock) and at 60%
confluency, were subjected to serum starvation overnight. Post overnight serum starvation,
cytokine treatment was performed using IL-6 and IL-6 + IL-1b, for 15 minutes. IL-6 and IL-1β
(R & D systems; cat# 206-IL and 201-LB, respectively) were used at concentrations of 10 ng/ml
and 1 ng/ml, respectively. Nuclear extracts were prepared using NE-PER nuclear and
cytoplasmic kit (Pierce; cat# 78835), as described previously (25). Putative STAT3-containing
oligonucleotide (oligo) sequences that are used in EMSA are shown in Figure 1B. Oligos were
obtained from Integrated DNA Technologies. Probes were prepared by annealing
complementary oligos, followed by labelling with [g 32P] ATP (MP Biomedicals; SKU
013502005) using end labelling with T4 Polynucleotide kinase ( Promega; M4101). Probenuclear extract reaction mixture was incubated in gel shift incubation buffer (40 mM KCl, 20
mM Hepes pH 7.9, 1 mM MgCl2, 0.05 mM EGTA, 0.5 mM dithiothrietol, 4% Ficoll, and 1 μg of
poly dI-dC) for 20 minutes at room temperature. For supershift experiments, antibody to STAT3
(F20X, Santa Cruz Biotechnologies) was added to the nuclear extract, prior to addition of the
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probe. DNA- protein complexes were resolved in 5% polyacrylamide native gels containing
2.5% glycerol and analyzed in a phosphorimager using ImageQuant software (GE Healthcare).

CRP Promoter-Luciferase (Luc) Reporter Constructs
The engineering of Luc-157 (−157/+1 of CRP gene and Luc-300 (-300/+3 of CRP
promoter) wild-type (WT) constructs, have been described previously (8,25,28). The WT
constructs were used as templates for mutagenesis. Constructs containing mutated STAT3 sites
were generated using the QuickChange site-directed mutagenesis kit (Stratagene) on both Luc157 WT and Luc-300 WT. The STAT3-site (-108) was mutated by substituting -111TCCCGA-106
with -111GATATC-106 using mutagenic primers 5'GCTTCCCCTCTGATATCAGCTCTGACACCTG and 5'CAGGTGTCAGAGCTGATATCAGAGGGGAAGC. The STAT3-site (-134) was mutated by
substituting -138TTCTGAAA-131 with -138TCCGGCCA-131 using mutagenic primers: 5'TCACATTGATTTCTCTGTCCGGCCATAATTTTGCTTCCCC and 5'GGGGAAGCAAAATTATGGCCGGACAGAGAAATCAATGTGA. The STAT3-site (-165)
was mutated by substituting -169TTGTAATAA-161 with -169TTCGCAGTA-161 using mutagenic
primers 5'GGTAATTCAGTAGTCATAGGAGTTCGCAGTACATAACTCACATTGATTTCTCTG and 5'CAGAGAAATCAATGTGAGTTATGTACTGCGAACTCCTATGACTACTGAATTACC. A
double STAT3 mutant with both -108 and -134 site mutated was generated by using Luc- 157
mut STAT3 (-108) and Luc- 300 mut STAT3 (-108) as the template and STAT3-site (-134)
mutagenic primers, as described above. Double STAT3 mutant with both -108 and -165 site
mutated was generated by using Luc- 300 mut STAT3 (-108) as the template and STAT3-site (-
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165) mutagenic primers, as described above. Plasmids were purified using maxiprep plasmid
isolation kit (Eppendorf) and mutations were verified by sequencing at the Molecular Biology
Core Facility at ETSU,

Luciferase (Luc) Transactivation Assay
Hep3B cells were cultured overnight for transfection and cytokine treatment using serumfree medium as described previously (26). The confluency of cells at the time of transfection was
approximately 60%. Cells were plated into 6-well plates for transient transfections, and
transfection was carried out using FuGENE 6 reagent (Promega). Briefly, per well, 10 µl
FuGENE 6 was added to 125 µl RPMI-1640 and incubated for 5 minutes. Further, 1µg of
Luciferase reporter-CRP promoter construct was added to the RPMI- FuGENE 6 cocktail,
incubated for 20 minutes at RT and added to the well. Cytokine treatment was performed 16
hours post-transfection. IL-6 and IL-1β (R & D systems) were used at concentrations of 10 ng/ml
and 1 ng/ml, respectively, and incubation continued for 24 hours. Post-transfection (40 hours)
and post-cytokine treatment (24 hours), luciferase assays were performed (Luciferase assay
system with reporter lysis buffer; Promega) as described previously (27). Luciferase activity was
measured in a luminometer (Molecular Devices), which was programmed for the integration
time of 10 s with no post-injection delay time. Results were projected as mean ± SD of three
experiments and statistical analysis was performed using unpaired student t-test.
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Results
Multiple IL-6 inducible putative STAT3-binding sites are located within the first 300 bp (300/+3) region of CRP promoter
We examined the proximal 300 bp region of the CRP promoter and located three
previously undescribed, putative STAT3-binding sites containing TT(N)4AA or TT(N)5AA
motifs. Two sites were located downstream of -157/+1 region of the CRP promoter, at -72 (-76/69: TTGGAAAA) and -134 (-138/-131: TTCTGAAA), while one was located upstream at -165
(-169/-161: TTGTAATAA) in the -300/+3 region (Fig 4.1 A).

A
-300

-165

-134

-108

-72

+3

CCC…..CATAGGAGTTTGTAATAAATAAC...TCTGTTCTGAAATAATTTTGC…TCTTCCCGAAGCTCTG…….CAATGTTGGAAAATTATTTAC….TCTAAG
GGG….GTATCCTCAAACATTATTTATTG…AGACAAGACTTTATTAAAACG…AGAAGGGCTTCGAGAC…...GTTACAACCTTTTAATAAATG….AGATTC
Putative STAT3
binding site 3

Putative STAT3
binding site 2

Known STAT3
binding site

B
Probes for EMSA:
Oligo 1 [ STAT3 (-72) ]

-92 5’ GCCCCAACAAGCAATGTTGGAAAATTATTTACATAGTGCG 3’ -53
GCGCACTATGTAAATAATTTTCCAACATTGCTTGTTGGGG

Oligo 2 [ STAT3 (-134) ]

-154 5’ GCGCGTGATTTCTCTGTTCTGAAATAATTTTTGCTGCGTG 3’ -115
GCACGCAGCAAAAATTATTTCAGAACAGAGAAATCACGCG

Oligo 3 [ STAT3 (-165) ]

-182 5’ GGCGCATAGGAGTTTGTAATAAATAACTCACCGC 3’ -149
GGCGGTGAGTTATTTATTACAAACTCCTATGCGC

Oligos used to construct mutated STAT Luc promoter:
WT
mSTAT (-108)

TTCCCGAA
5’ GCTTCCCCTCTGATATCAGCTCTGACACCTG 3’
CAGGTGTCAGAGCTGATATCAGAGGGGAAGC

WT
mSTAT (-134)

TTCTGAAA
5’ TCACATTGATTTCTCTGTCCGGCCATAATTTTGCTTCCCC 3’
GGGGAAGCAAAATTATGGCCGGACAGAGAAATCAATGTGA

WT
mSTAT (-165)

TTGTAATAA
5’ GGTAATTCAGTAGTCATAGGAGTTCGCAGTACATAACTCACATTGATTTCTCTG 3’
CAGAGAAATCAATGTGAGTTATGTACTGCGAACTCCTATGACTACTGAATTACC

106

Putative STAT3
binding site 1

Figure 4.1: The −300 / +3 region of the CRP gene promoter and the sequences of the
oligos used in this study. (A) The putative binding sites for STAT3 on the CRP promoter
are shown along with the previously known STAT3 binding site at -108. (B) Sequence of
the oligos used as probes in EMSA and to construct mutated STAT promoter for
luciferase assays. Putative STAT3 binding sites are shown, highlighted in blue. Mutated
nucleotides are indicated in red.

IL-6 activated STAT3 binds to its cognate site at position -134 and -165 on CRP promoter
Binding of STAT3 to the newly identified putative STAT3-binding sites on the CRP
promoter was analyzed by EMSA. Nuclear extracts from Hep3B cells treated with IL-6 alone
and (IL-6 + IL-1b; 15 minutes) were used as source of activated STAT3. Wild- type (WT)
oligos, containing putative STAT3 sites (-72, -134, and -165), are shown in Fig 4.1 B. When WT
oligo (-72) was used as probe, several complexes were observed (Fig 4.2 A), however, none
were clearly abolished or super-shifted by inclusion of anti-STAT3 antibodies. Two STAT3containing complexes were observed with WT oligo (-134) as probe (Fig 4.2 B). The intensity of
the two bands was greater using nuclear extracts from (IL-6 + IL-1b)-treated Hep3B cells
compared to nuclear extracts from cells treated with IL-6 alone. Using nuclear extracts from IL6 treated cells, only one band (complex II) was clearly visible (Fig 4.2 B, lane2), which was
supershifted by anti-STAT3 antibody (Fig 4.2 B, lane 4). Nuclear extracts from (IL-6 + IL-1b)treated cells, produced two bands ( Complex I and complex II) (Fig 4.2 B, lane3) both of which
were abolished in the presence of anti- STAT3 antibody (Fig 4.2 B, lane 5). EMSA revealed one
STAT3-containing complex formed with WT oligo (-165) with nuclear extracts from both IL-6
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(Fig 4.2 C, lane 2) and (IL-6 + IL-1b) (Fig 4.2 C, lane 3) treated cells. Although the intensity of
the EMSA bands observed with WT oligo (-165) was not as intense as those observed with WT
oligo (-134) and WT oligo (-72), they were abolished in the presence of anti- STAT3 antibody
(Fig 4.2 C, lane 4 and 5 respectively). The abolition of complexes by anti-STAT3 antibodies
observed with WT oligo (-134) and WT oligo (-165) confirms that these complexes contain
STAT3. Therefore, out of the identified, putative STAT3 binding sites, STAT3 was shown to
bind to -134 and -165.
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Figure 4.2: STAT3 binds to its cognate position at -134 and -165. A representative
EMSA demonstrating the binding of STAT3 to its putative binding sites on the CRP
promoter is shown. Radiolabeled WT oligos [ (A) Oligo 1: -72 (-92/-55), (B) Oligo 2: 134 (-154/-115), and (C) oligo 3: -165 (-182/-149) ] were used as probe and nuclear
extract derived from cytokine (IL-6 and IL-6 + IL-β; 15 minutes)-treated Hep3B cells
were used as the source of STAT3. Anti-STAT3 was added to nuclear extracts before the
addition of the probe. DNA probe–protein complexes were visualized using a
phosphorimager. Complexes containing STAT3 are indicated by arrows and free probe
mobility is not shown.
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The proximal 157bp region of the CRP promoter is sufficient for transactivation but -300/+3
region elicits a greater response
The proximal 157 bp region of CRP promoter has been shown to be sufficient for
synergistic induction of CRP gene expression. We compared the transactivation of CRP gene
expression between the proximal 157 bp (Luc 157-WT) and 300 bp (Luc 300-WT) region of
CRP promoter by Luciferase transactivation assays (Fig 4.3 A). The synergy between IL-6 and
IL-1b was observed with both Luc-157 WT and Luc-300 WT, with the CRP expression being
~90 % greater (*; p = 0.004) in cells treated with (IL-6 + IL-1b) as compared to cells treated
with IL-6 alone. IL-1b-treated cells displayed similar transactivation as basal (data not shown).
In all cells treated with IL-6 alone and in cells treated with (IL-6 + IL-1b), Luc-300-WT
displayed a greater transactivation that Luc-157 WT [~53% and ~33% (*) respectively]. These
results indicate that the region between -157 and -300 contribute to an elevated CRP gene
expression.
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Figure 4.3: The -300/+3 region of CRP promoter elicits a greater cytokine-induced
response when compared to the proximal 157 region and the STAT3 site at -108 is
critical for CRP transcription. (A) Luciferase transactivation assay of Hep3B transfected
with Luc-157 WT and Luc-300 WT CRP promoter constructs is shown. ((B-D)
Luciferase transactivation assay showing the effect of mutated STAT3 site at -108 on
cytokine (IL-6 and IL-6 + IL-1β)-induced CRP expression, is shown. Hep3B cells were
transfected with Luc-157 WT and Luc-157 mS (-108) (B), Luc-300 WT and Luc-300 mS
(-108) (C), and Luc-157 mS (-108) and Luc-300 mS (-108) (D) CRP promoter constructs,
24 h post cytokine treatment and 40 h post transfection, CRP transcription was measured
as Luc activity. Fold change over basal luciferase activity is plotted on the x-axis. Results
are expressed as mean ± SD for three experiments. p value of < 0.05 are considered
statistically significant (*).
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Role of STAT3-site positioned at -134 in IL-6 and (IL-6 + IL1-b)- induced CRP expression
The binding of STAT3 to its transcriptionally active site at -108 has been well
documented (13) and as shown in Fig 4.3 B and 4.3 C, mutation of STAT3 (-108) leads to
reduced IL-6 and (IL-6 + IL-1b) induced gene expression in both proximal 157 and 300 bp
region of CRP promoter. However, mutation of STAT3 (-108) in the proximal 300 bp region did
not completely abolish the activation of CRP expression by IL-6, unlike the proximal 157 bp
region (Fig 4.3 D).
To investigate the role of potential STAT3 binding site at -134, in regulating cytokine
[IL-6 and (IL-6 + IL1-b)] induced CRP expression, we performed Luciferase transactivation
assays using Luc 157-WT, Luc 300-WT, Luc 157-mS (-134), and Luc 300-mS (-134) promoter
constructs. In addition, CRP promoter constructs with mutation in both (-108 and -134) STAT3
sites [Luc-157 mS (-108) + (-134) and Luc-300 mS (-108) + (-134)], were used to analyze the
combined function of of STAT3 on CRP promoter activity in response to IL-1b, IL-6, and (IL-6
+ IL-1b) induced CRP expression respectively. Treatment with IL-1b alone did not induce CRP
expression above basal levels (data not shown). Mutation of STAT3 (-134) in the 157 bp region
of CRP promoter, Luc-157 mS (-134) has no effect on (IL-6 + IL-1b)- induced CRP expression
while the IL-6 induced CRP expression was ~47 % higher (*; p = 0.04) compared to Luc-157
WT (Fig 4.4 A). However, mutation of STAT3 (-134) in the 300 bp region, Luc-300 mS (-134)
resulted in greater IL-6 and (IL-6 + IL1-b) -induced CRP expression (~88% and ~40% (*),
respectively) (Fig 4.4 B). Consistent with results for mutation of STAT3 (-108), mutating
STAT3 (-134) in the proximal 300 bp region of CRP promoter produced a higher CRP
expression as compared to the same mutation in the proximal 157 bp promoter region (Fig 4.4
C).
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Mutation of both STAT3 sites (-108 and -134), Luc-300 mS (-108) + (-134) completely
eliminated IL-6 and (IL-6 + IL1-b)-induced CRP expression when compared to Luc 300-WT
(Fig 4.4 E). However, mutation of both STAT3 sites in the 157 bp region, Luc-157 mS (-108) +
(-134) induced ~49% lower (*) (IL-6 + IL-1b)- induced CRP expression compared WT and no
effect was observed in IL-6-induced CRP expression (Fig 4.4 E). Mutation of STAT3 sites at 108 and -134 in the proximal 300 bp region of the promoter lead to loss of the cytokine-induced
CRP expression, however, the cytokine-induced CRP expression was observed in the 157 bp
promoter region with both STAT3 sites mutated (Fig 4.4F).
As reported previously (13) and shown here, the STAT3 (-108) site is involved in
activating CRP transcription as its mutation reduced (IL-6+IL-1b)-induced CRP expression in
both proximal 157 bp and 300 bp region. Our results suggest that the STAT3 (-134) site alone
does not contribute to enhance CRP expression but rather regulates the interaction/crosstalk
between other transcription factors as mutation of this site enhanced CRP expression in the
proximal 300 bp region but not in 157 bp promoter region. Consistent with this, is the
observation that complete elimination of STAT3 binding sites (mutated -134 and -108) reduced
CRP expression to basal levels. This raises the possibility of the involvement of an active site
present between -300 bp and -157 bp region that is involved in the crosstalk. Also, because the
effect is observed in both IL-6 and (IL-6+IL-1b)-induced CRP expression, IL-6 activated
transcription factors appear to be involved in the crosstalk. Compared to the proximal 157 bp
region of CRP promoter, the proximal 300 bp of CRP promoter elicits a greater cytokine induced
CRP expression. Mutation of -108 site or -134 site alone did not significantly affect this
observation. When both STAT3 sites were mutated in the proximal 300 bp region, the cytokineinduced expression of CRP gene was reduced to basal levels, however a similar effect was not
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observed on the cytokine-induced CRP expression in the proximal 157 bp region. This further
supports the possibility of a crosstalk mechanism between transcription factors present in the
proximal 300 bp promoter region and STAT3 sites (-108 and -134) along-with other
transcription factors present in -157 bp region of CRP promoter.
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Figure 4.4: STAT3 binds to its cognate site at position -134 on the CRP promoter and
regulates cytokine (IL-6 and IL-6 + IL-1β)-induced CRP expression. (A-C) Luciferase
transactivation assay shows the effect of mutated STAT3 site at -134 on cytokine (IL-6
and IL-6 + IL-1β)-induced CRP expression. Hep3B cells were transfected with Luc-157
WT and Luc-157 mS (-134) (A), Luc-300 WT and Luc-300 mS (-134) (B), and Luc-157
mS (-134) and Luc-300 mS (-134) CRP promoter constructs. (D-F) A luciferase
transactivation assay, where the effect of mutated STAT3 sites at -108 and -134 on
cytokine (IL-6 and IL-6 + IL-1β)-induced CRP expression, is shown. Hep3B cells were
transfected with Luc-157 WT and Luc-157 mS (-108) + (-134) (D), Luc-300 WT and
Luc-300 mS (-108) + (-134) (E), and Luc-157 mS (-108) + (-134) and Luc-300 mS (-108)
+ (-134) (F) CRP promoter constructs at 24 h post cytokine treatment and 40 h post
transfection, CRP transcription was measured as Luc activity. Fold change over basal
luciferase activity is plotted on the x-axis. Results are expressed as mean ± SD for three
experiments. p value of < 0.05 are considered statistically significant (*).

STAT3 binds to its cognate site at -165 but does not participate in the transcriptional activation
of CRP gene expression
In order to investigate the role of STAT3 (-165) in cytokine [IL-6 and (IL-6 + IL1-b)]
induced CRP expression, we performed Luciferase transactivation assays using Luc 300-WT,
and Luc 300-mS (-165) promoter constructs, as well a, CRP promoter constructs with both -108
and -165 STAT3 sites mutated, Luc-300 mS (-108) + (-165). IL-1b-induced CRP expression was
similar to basal expression (data not shown). Mutation of STAT3 at -165 in the 300 bp promoter
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region, Luc-300 mS (-165) did not affect the cytokine induced CRP expression (Fig 4.5 A).
However, mutation of STAT3 at both -108 and -165, significantly reduced (IL-6 + IL-1b)induced CRP expression by ~75% (* ) (Fig 4.5 B), but when compared with mutation of STAT3
at -108 and -134, the cytokine induced CRP expression is significantly greater (Fig 4.5 C).
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Figure 4.5: STAT3 site at -165 neither activates nor regulates cytokine (IL-6 and IL6 + IL-1β)-induced CRP expression. Luciferase transactivation assays of Hep3B cells
transfected with Luc-300 WT and Luc-300 mS (-165) (A), Luc-300 WT and Luc-300 mS
(-108) + (-165) (B), and Luc-300 mS (-108) + (-134) and Luc-300 mS (-108) + (-165)
CRP promoter constructs at 24 h post cytokine treatment and 40 h post transfection, CRP
transcription was measured as Luc activity. Fold change over basal luciferase activity is
plotted on the x-axis. Results are expressed as Mean ± SD for three experiments. p value
of < 0.05 are considered statistically significant (*).

These results indicate that the putative STAT3 site at -165 does not play a significant role
in either activating or regulating CRP gene expression as the cytokine induced CRP expression
after mutating STAT3 site at -165 was not different than WT. Furthermore, since mutation of
STAT3 at -108 alone reduces cytokine induced CRP expression, the effect of abolition of both
STAT3 site at -108 and -165 did not contribute enough to the CRP gene expression.
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Discussion
The aim of the study was to locate additional transcriptionally active, IL-6-inducible
STAT3 binding sites in the -300/+3 region of the CRP promoter. Our major findings were 1)
Multiple putative IL-6 inducible STAT3 binding sites, centered at position -72, -134, and -165, 134, are located in the proximal -300 bp region of CRP promoter,. 2) IL-6 activated STAT3
binds to its cognate site at position -134 and -165, in addition to binding to another previously
identified site at position -108. 3) STAT3 binds to its cognate site positioned at -165 but it does
not activate or regulate CRP gene transcription. 4) Cytokine [IL-6 and (IL-6 + IL-1b)]- induced
CRP expression increased dramatically when STAT3 site positioned at -134 was mutated,
however, CRP expression curtailed back at basal levels when STAT3 was unable to bind to
either of its two sites (-134 and -108) on the CRP promoter. This effect of STAT3 was observed
only in the proximal 300 bp region and not in the 157 bp region. Taken together, these data
suggest that in addition to transcriptionally active STAT3 site at position -108, STAT3 binds to
another site centered at -134 but unlike STAT3 (-108), STAT3 (-134) does not activate
transcription but rather regulates the crosstalk of STAT3 (-108) with C/EBPb (-222) and
C/EBPb-b-NFkB complex (-52/-47) in the -300/+3 region of CRP promoter.
In humans, the acute phase nature of CRP has been observed in various acute and chronic
inflammatory states (1-6). Because CRP is a hepatocyte derived protein, the regulation of its
synthesis at the transcriptional level has been studied and observed in various hepatocyte derived
cell lines such as Hep3B. The activation of CRP gene expression occurs in response to IL-6 and
IL-1b wherein IL-6 induces CRP expression via activation and binding of transcription factor
C/EBPβ to its sites centered at position -52 and -222 and STAT3 to its site centered at position -
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108 respectively, on the CRP promoter (12,13,17, 26, 29). IL-1b alone, in contrast, does not
induce CRP expression but rather synergistically enhances IL-6 induced expression via
activation and binding of NF-kB to its site centered at position -69 and a nonconsensus kB site
centered at position -47 on the CRP promoter (8,9,25). Initially, the proximal 157 bp region of
CRP promoter was found to be sufficient to induce CRP expression (9,13) but later it was
reported that the proximal 300 bp region induces more CRP expression compared to the 157 bp
region alone. One of the possible explanations for the differential induction of CRP expression
between the -157/+1 and -300/+3 regions of the promoter can be attributed to the presence of an
additional C/EBPb site at position -222. No additional NF-kB sites have been found between 157 bp and -300 bp region of CRP promoter. Also, in the proximal 300 bp region of the CRP
promoter, the presence of additional STAT3 responsive sites have not been sought yet.
In the current study, we found multiple putative IL-6 inducible STAT3 binding sites,
located at position -72, -134, and -165 respectively, in addition to the previously reported
transcriptionally active STAT3 site at position -108. Out of these newly identified putative
binding sites, STAT3 was found to bind to its cognate site at position -134 and -165. Although,
STAT3 binds specifically to TT(N)4AA or TT(N)5AA motifs, the spacing between the TT and
AA core half-sites affects the ability of STAT3 to bind to its responsive elements on the CRP
promoter. Other STAT complexes have the ability to bind to TT(N)5AA motifs while STAT3
binds specifically to TT(N)4AA motifs (30). This explains the inability of putative STAT3 site
positioned at -165 to activate transcription since it contained TT(N)5AA motif. The other
putative STAT3 site at -72 remains to be evaluated and studied further since this area of CRP
promoter contains overlapping binding sites for various constitutively active transcription factors
such as HNF-1, HNF-3 and a repressive transcription factor Oct-1 along with a NF-kB binding
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site (8,12,19,32).
Fig 4.6 depicts our hypothetical model based on the findings in the current study
illustrating the role of STAT3 site at position -134 in regulating CRP gene expression. The
proposed mechanism of regulation of CRP gene transcription in lieu of STAT3 (-134) is as
follows: 1. As shown in Fig 4.5 A, when IL-6 activated STAT3 binds to its cognate site at
position -134 and -108, CRP transcription is activated by STAT3 (-108) and other transcription
factors; 2. Mutation or abolition of STAT3 (-134) leads to enhanced IL-6 and (IL-6 + IL-1b)induced CRP expression in contrast to STAT3 (-108) wherein its abolition leads to decreased
CRP expression. The effect of mutation or abolition of STAT3 (-108) on CRP expression is
observed only in (IL-6 + IL-1b)- induced transcriptional activation and not in IL-6 induced
transcriptional activation alone; 3. Also, abolition of both STAT3 binding sites, i.e., STAT3 (108) and STAT3 (-134) completely diminishes CRP expression down to basal levels. Therefore,
STAT3 (-134) acts as a regulatory site for STAT3 (-108) wherein it regulates the crosstalk of
STAT3 (-108) with other transcription factors. Since, similar effect of STAT3 (-134) is not
observed in proximal 157 bp region, we hypothesize that C/EBPb site at position -222 is
involved in the crosstalk with STAT3 (-108). Along with it, the discrepancy in the IL-6 and (IL-6
+IL-1b)-induced activation of CRP transcription by STAT3 (-108) further raises the possibility
of the involvement of NFkB in the crosstalk mechanism since NFkB is the only transcription
factor induced by IL-1b; and 4. Taken together, as shown in Fig 4.6 B, the absence of STAT3 (134) enables STAT3 (-108) to cross talk and form a complex with C/EBPb (-222) and this
STAT3- C/EBPb complex further cross-talks with C/EBPb-NFkB complex (-52/-47).
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Figure 4.6: A hypothetical model representing the role of STAT3 site at position -134 in
regulating CRP expression. (A) Cytokines [IL-6 and (IL-6 + IL-1b)] induce CRP
expression of WT promoter (-300/+3) via activation of various transcription factors such
as C/EBPb (-222; brown), STAT3 (-134 & -108; yellow), and C/EBPb-NFkB complex (-
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69/-52; green). Mutation of STAT3 (-134) increases cytokine induced CRP expression
while mutation of STAT3 (-108) decreases (IL-6 + IL-1b)-induced CRP expression. (B)
Deletion of STAT3 (-134) allows STAT3 (-108) to crosstalk with C/EBPb (-222) and this
C/EBPb-STAT3 complex further cross-talks with C/EBPb- NFkB complex (-69/-52).
These cross-talks, highlighted in red, mediates cytokine induced CRP expression.

The mechanism of synergy or crosstalk between C/EBPb, STAT3, and NF‐κB has been
observed in transactivation of CRP gene expression (33). In addition to CRP gene promoter,
synergy between these transcription factors has also been observed to induce expression in
promoters of various other model proteins such as synergistic interaction between NF‐κB and
C/EBPβ (26,27,29,35-37), NF‐κB and STAT proteins (37-40), and C/EBPβ and STAT proteins
(41-44). Our observation that STAT3- C/EBPb complex (-222/-108) crosstalk with C/EBPbNFkB complex (-52/-47) is based on the previously reported studies that shows that NF-κB p65
inhibits STAT3 dependent activation of gene. Therefore, STAT3 cannot crosstalk with NF-κB
site at position -69 since it contains p50-p65 heterodimers. In contrast, NF-κB p50 acts in
synergy with STAT3 to activate gene transcription (20) and NF-κB p50 has been reported to
form a complex with C/EBPb on the CRP promoter via the nonconsensus κB site (-47)
overlapping the proximal C/EBP binding site (-52) (26). Another critical regulatory region on the
CRP promoter that participates in transactivation of CRP gene is the -54 to -74 region, where
NF-κB, HNF-1, HNF-3, and Oct-1form complexes. STAT3 has been reported to form a
transcriptional complex with c-Fos and HNF-1a that aid in the synergistic induction of CRP
gene expression (45). This raises the possibility that STAT3 might be involved in regulating
CRP gene expression via the -54 to -74 region. However, this is just a speculation and needs to
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be studied in detail further.
In summary, we report another STAT3 binding site at position -134 in addition to the
transcriptionally active STAT3 site at position -108 and in contrast to STAT3 (-108) that
activates transcription of the CRP gene, STAT3 (-134) regulates CRP transcription by regulating
the STAT3 (-108). This study also provides a proof of principle for a possible mechanism of
crosstalk between STAT3 (-108), C/EBPb (-222) and C/EBPb-NF-κB p50 (-52/-47). Further
studies using overexpressed STAT3 would provide more insight into the mechanism of
activation and transcriptional regulation of CRP gene by STAT3. Also, future studies at
chromatin levels need to be addressed as transiently transfected promoter constructs are not
appropriate models for endogenous genes due to the packaging of these genes in chromatin
structures (46).
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CHAPTER 5
SUMMARY
The major findings of our studies were:
1. A non-native pentameric CRP, F66A/T76Y/E81A mutant CRP, created by site-directed
mutagenesis, binds to atherogenic LDL at physiological pH, i.e, it does not need the
presence of an acidic environment to do so unlike native pentameric CRP.
2. F66A/T76Y/E81A mutant CRP demonstrated protection against atherosclerosis by
decreasing the extent of atherosclerotic lesions along the aorta and slowing the
progression of the disease. This atheroprotective effect of mutant CRP was observed in a
site-specific manner as it showed an effect on lesion area in the whole aorta of HFD-fed
LDLR-/- mice but had no effect on the size of atherosclerotic lesions in the aortic root.
3. Administration of F66A/T76Y/E81A mutant CRP did not affect the lipoprotein, i.e.,
HDL and LDL profile of HFD-fed LDLR-/- mice. Therefore, non-native pentameric
human CRP that is a structurally altered form of native pentameric human CRP, is an
atheroprotective molecule.
4. CRP from an evolutionary distant species Limulus Polyphemus, Limulus CRP, is different
than native pentameric human CRP. Limulus CRP is a 300 kDa protein that exists as a
dodecamer with two rings of six subunits each with differential glycosylation patterns, as
opposed to human CRP which is a 120 kDa pentameric, non-glycosylated protein.
5. Limulus CRP exists in different isoforms that possess differential affinities for PCh and
PEt containing ligands. Limulus CRP, purified either by PCh or by PEt, can recognize
and bind to immobilized, denatured, and aggregated proteins in a calcium independent
manner, at physiological pH.
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6. The ligand recognition function of Limulus CRP is different than native pentameric
human CRP but overlaps that of the non-native pentameric human CRP.
7. Therefore, ancient CRP such as Limulus CRP, inherently had the ability to bind to
pathogenic proteins in a physiological environment. However, over the course of
evolution, the structure of CRP changed and in order for CRP to recognize and bind to
such pathogenic and toxic proteins an acidic or inflammatory environment was needed.
8. The proximal 300 bp region of human CRP promoter elicits a higher IL-6 mediated
response when compared to the proximal 157 bp region. The proximal 300 bp region was
found to contain three putative STAT3 binding sites, centered at position -165, -134, and
-72, in addition to the known transcriptionally active site at position -108.
9. Amongst the identified, putative STAT3 binding sites, IL-6 activated STAT3 was found
to bind to its cognate site at positions -134 and -165, in addition to binding to another
previously identified site at position -108.
10. Cytokine [IL-6 and (IL-6 + IL-1b)]- induced CRP expression was shown to increase
dramatically when STAT3 was unable to bind to its site positioned at -134, however,
CRP expression curtailed back at basal levels when STAT3 was unable to bind to either
of its two sites (-134 and -108) on the CRP promoter. This effect was observed only in
the proximal 300 bp region and not in the 157 bp region. Taken together, these data
suggest that in addition to transcriptionally active STAT3 site at position -108, STAT3
binds to another site centered at -134 but unlike STAT3 (-108), STAT3 (-134) does not
activate transcription but rather regulates the cross-talk of STAT3 (-108) with possibly,
C/EBPb (-222) and C/EBP-b-NFkB complex (-52/-47) in the -300/+3 region of CRP
promoter.
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CRP has been linked to atherosclerosis, a chronic inflammatory disease, in terms of
higher circulating levels, deposition at atherosclerotic lesion, and co-localization with LDL and
macrophages within lesions. To elucidate the role of CRP as either a pro-atherogenic protein or
an anti-atherosclerotic protein, various studies were performed using different animal models of
atherosclerosis wherein native CRP was administered either passively or transgenically. In all
studies, CRP was found to be neither pro-atherogenic nor anti-atherosclerotic with the exception
of one study (84), where CRP was shown to slow the progression of the disease.
Human CRP has been shown to exists in two pentameric structural conformations, native
and non-native and the ligand recognition functions of these two structural conformations differ.
A micro-inflammatory environment is required by CRP to change its structure from a native
pentameric state to a non-native pentameric state, that can be achieved in vitro by exposure to
biological modifiers such as hydrogen peroxide, hypochlorous acid or even acidic pH, but this
structural change is reversible at physiological pH. Non-native pentameric CRP acquires the
property to recognize and bind to immobilized, aggregated, and pathogenic proteins as opposed
to native pentameric CRP. Previous lab studies have shown that native CRP binds to E-LDL at
physiological pH and this CRP-E-LDL complex prevents foam cell formation (88). However, it
does not bind to ox-LDL unless the LDL is sufficiently oxidized to expose its PCh moieties.
Non-native CRP binds to E-LDL with higher avidity compared to native CRP and binds to oxLDL irrespective of the extent of oxidation.
Atherosclerotic lesions are often characterized as inflammatory sites wherein acidic pH
predominates along with changes in the redox environment due to free radical generation.
Further extending our current understanding of the role of CRP in atherosclerosis is the fact that
the disease development differs between animal models and humans. This raises the possibility
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that the atherosclerotic lesions in animal models might lack a suitable acidic micro-environment
necessary for native CRP to undergo the required structural change and therefore, could not bind
to atherogenic LDL. In this study, we used a modified CRP, F66A/T76Y/E81A (mutant CRP),
created by site-directed mutagenesis, that binds to atherogenic LDL without the requirement of
an acidic pH and we found that this mutant CRP delays and inhibits the progression of
atherosclerosis in a site specific manner using LDLR-/- mouse models.
This study provides a proof of principle for the atheroprotective ability of CRP, wherein
non-native CRP can be used as a novel therapeutic tool for treatment against atherosclerosis. One
of the drawbacks of this study is that it is a single dose-one regimen model. There is a possibility
that the amount of CRP administered was inadequate and CRP was not able to display an affect
in its full capability, as we observed a site-specific atheroprotective effect. Future studies
employing a non-native CRP transgenic mouse model on LDLR-/- background may provide
further validation of the atheroprotective ability of this molecule along-with a comparative study
using another atherosclerosis mouse model such as HFD-fed ApoE-/- mice. Another drawback is
that no mechanism of action regarding how CRP affected the development and progression of
atherosclerosis could be defined. The proposed mechanism of action is that non-native CRP
recognizes and binds to modified LDL and prevents foam cell formation by blocking their uptake
by macrophages. Further studies to support the proposed mechanism of action and to define
other potential mechanisms that are responsible for the observed protective effect of CRP in
atherosclerosis, are required. Atherosclerosis, being a major cause of cardiovascular mortality in
developed countries, and inflammation playing a major role in it, constantly compels the need to
find alternative treatments as available treatments such as statins or other cholesterol lowering
drugs presents with side-effects and the natural treatment provide with contradictory results.
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Using a slightly altered component of the immune system itself, as a therapeutic molecule might
prove to be beneficiary.
CRP is an evolutionarily conserved protein that has been found in every organism where
its presence has been sought. Over the course of evolution, the structure of CRP changed. Based
on our finding in the study above, that a non-native pentameric human CRP acts as an
atheroprotective molecule, it is imperative to understand the evolution of the structural change of
CRP. Therefore, a parallel comparison of structure-function relationship of CRP between an
evolutionary distant specie and humans would be useful. The conservation of CRP amongst
various species across the animal phyla, led us to conclude that CRP is an important molecule of
the immune system as it evolved along with the development of the entire immune system in
terms of its structure and function. The sites that are relevant for the function of CRP, such as
PCh-binding site, C1q-binding site, and an intrinsically disordered region, are also conserved
amongst different species.
Using Limulus polyphemus as a model invertebrate organism that is also an evolutionary
distant species, we studied the evolution of function CRP in terms of its structure. Unlike human
CRP, Limulus CRP is a glycosylated protein that has varying affinities for PCh and PEt ligands.
Surprisingly, human CRP do possess sites of glycosylation but they are hidden in its native
conformation and therefore provide no functional advantage to native CRP. Limulus CRP is
known to exist in three isoforms due to variable glycosylation (54). The isoform of Limulus CRP
that has higher affinity for PCh was called as CRP-I (PCh-binding Limulus CRP) and the one
that has higher affinity for PEt was called CRP-II (PEt-binding Limulus CRP). In order to see if
these carbohydrate moieties have any role in the structure-ligand function of Limulus CRP, we
de-glycosylated both CRP-I and CRP-II and found that the ability of these proteins to recognize
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and bind to immobilized, denatured and aggregated proteins significantly decreased
(approximately 100 fold) when compared to its glycosylated counterparts. However, upon
exposure to acidic environment, they regained their ligand-recognition function. Therefore, deglycosylated Limulus CRP behaves similar to native human CRP and native glycosylated
Limulus CRP behaves similar to non-native human pentameric CRP. We conclude that though
the ligand-binding properties of Limulus CRP are not identical to that of native human CRP, they
overlap the ligand-binding properties of non-native pentameric human CRP that can be generated
in inflammatory microenvironments. Also, changing the glycosylation state of Limulus CRP,
alters its ligand-binding property to overlap with that of native human CRP.
The drawback of our study is that we could not de-glycosylate the protein completely and
hence, could not understand the importance of the presence of carbohydrate moieties on the
protein, since glycosylation is the major aspect where Limulus CRP differs from human CRP.
Additionally, the enhanced ability of Limulus CRP to recognize and bind pathogenic proteins, in
the presence of an acidic environment could not be understood. Further studies are required to
understand the ligand-recognition functions between human CRP and Limulus CRP, in lieu of
the glycosylation pattern along-with the presence of an acidic environment. In our study above,
we showed the atheroprotective ability of a non-native pentameric human CRP whose ligand
recognition functions parallels with native Limulus CRP. These effector functions of CRP that
lies downstream of the recognition functions are dependent on the structural changes in the
protein. Studies on structure-function relationships of CRP from most species is unknown and
more studies are required from all species including invertebrate and vertebrate in order to have a
complete understanding of the evolution of this protein.
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Over the course of evolution, in addition to the structure, it appears that the gene
expression of CRP changed from a constitutive protein to an acute phase protein. The
concentration of CRP increases drastically, from several hundred to thousand fold, following an
inflammatory stimulus. The regulation of CRP gene expression occurs at transcriptional level via
various cytokine induced and constitutively active transcription factors. Since, CRP is a
hepatocyte derived protein, various hepatic cell lines have been used to study its gene expression.
Hep3B is the most commonly used cell line and the major cytokines that drive CRP transcription
in these cell lines are IL-6 and IL-1b. IL-6 alone, or in synergy with IL-1b induces CRP
expression. The proximal 157 bp region of the CRP promoter has been shown to be sufficient to
induce CRP transcription in response to IL-6. We recently found that the proximal 300 bp region
of the CRP promoter elicits a greater IL-6 response compared to the 157 bp region.
A previous study identified STAT3, an IL-6 inducible transcription factor, in activating
CRP gene transcription via binding to its site at position -108 on the promoter (83). In this study,
we identified multiple IL-6 inducible STAT3 binding sites on the proximal 300 bp region of
CRP promoter. We found that, in addition to transcriptionally active STAT3 site at -108, STAT3
binds to its cognate site at position -134. We propose that instead of activating CRP expression,
this site regulates CRP transcription via possibly regulating the cross talk between STAT3 at 108 and other IL-6 and IL-1b inducible transcription factors. This study provides a proof of
principle for a possible mechanism of crosstalk between STAT3 (-108), C/EBPb (-222) and
C/EBPb-NF-κB p50 (-52/-47).
The drawbacks of the study are that these findings are Hep3B cell line specific and
studied on a defined, short DNA sequence of CRP promoter. It is possible that the present study
for understanding the induction of CRP transcription in response to cytokines might not be
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reproducible when using transgenic mice as the defined conditions and cytokine treatments used
might not correlate with the physiological system of the transgenic mice (85). In addition,
transcription of CRP or any gene occurs via interaction of variable transcription factors that
regulates the transcription of the gene either positively or negatively. In vitro transcriptional
studies using shorter DNA sequences might produce results that could not be reproduced when
longer sequences are used, as some regulatory elements might be located several base pairs away
(86). Future studies using longer DNA sequences of CRP promoters and overexpressed STAT3
would provide more insight into the mechanism of activation and transcriptional regulation of
CRP gene by STAT3. Additionally, these findings need to be reproduced by using other
hepatocyte derived cell lines such as HepG2, Huh7, and primary human hepatocytes. Also,
future studies at the chromatin levels needs to be addressed as transiently transfected promoter
constructs are not appropriate models for endogenous genes due to the packaging of these genes
in chromatin structures (87).
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APPENDIX
Supplemental data for Chapter 2
CRP is an atheroprotective molecule

Methods
Atherosclerotic lesion measurement in the aorta (en face)
Formalin-fixed aortae were cut open longitudinally (en face) and pinned flat on a
standard black wax dissection pan using 0.15 mm black anodized pins. Pinned aortae were
stained with Sudan IV for lipid rich deposits in atherosclerotic lesions. Briefly, aortae were first
washed with 1X PBS and then with 70% ethanol for 5 minutes. Aortae were stained with Sudan
IV solution [0.5% Sudan IV in an acetone-absolute ethanol solution (1:1)] for 15 minutes and
then washed with 80% ethanol for 3 minutes in order to remove background stain. Aortae were
then washed with running water followed by 1X PBS. Pinned aortae were digitally
photographed. Thus, a total of 120 aortae (60 for untreated group and 60 for mutant-CRP treated
group) were processed and stained. The atherosclerotic lesion area (red colored deposits) was
determined and measured using ImageJ software.

Aortic root atherosclerotic lesion measurement
For aortic root atherosclerotic lesion measurement, OCT-embedded heart tissue along
with aortic root was mounted in a Leica CM1850 cryostat. 8-μm cross-sections were collected
starting at the first appearance of the aortic valve leaflets, on a Superfrosted plus microscope
slide (Fisher, cat# 12-550-15). Cross-sections were collected until the of the aortic valve leaflets
disappearance and alternating cryosections from each mouse were stained with oil-red O for
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lipids and counterstained with hematoxylin. Briefly, cryosections were air dried at RT for 30-40
minutes and then incubated in ice-cold neutral-buffered 10% formalin for 10 minutes followed
by rinsing using tap water first and then with distilled water (DI). Cryosections were then
incubated in 60% isopropanol (diluted with water) for 45 seconds and stained with fresh Oil Red
O solution (ORO: Stock ORO - 0.5g ORO powder in 100 ml isopropanol; working ORO- 60 ml
stock ORO + 40 ml DI) for 15 minutes under constant, low agitation. Following staining,
cryosections were rinsed with 60% isopropanol for 30 seconds first and then twice with DI.
Cryosections were counterstained with hematoxylin for 30 seconds and rinsed in running tap
water for 3 minutes. Cryosections were then mounted with a water-soluble mounting medium
(glycerol gelatin) at 55 oC. Images were digitally captured with an Olympus BX41 microscope
equipped with a MicroPublisher 5.0 RTV CCD color camera (QImaging). Thus, a total of 120
hearts (60 for untreated group and 60 for mutant-CRP treated group) were processed.
Approximately 48-72 cross-sections were collected per heart and every alternate cross-section
were stained for lipids. Lesions in the aortic root (red colored areas) were measured using the
Image-J software. Measurements were performed in a blind fashion.

CRP immunostaining
Cryosections were thawed, air dried for 1 hour and, fixed in ice-cold acetone for 10
minutes. Sections were then washed with 1X PBS for 5 minutes, air dried and circled using a
hydrophobic barrier (ImmEdge, Vector laboratories, cat # H-4000). Immunostaining was
performed with Vectastain ABC Elite kit (Vector laboratories, cat # PK-6100) and
manufacturer’s instructions were followed. CRP was detected with Rabbit anti-CRP (Millipore,
10 µg/ml/section). Color was developed using DAB as substrate (Vector laboratories, ImmPACT
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DAB, cat # SK-4105). Macrophages were detected with Rabbit anti-CD68 for pan macrophages
(ThermoFisher Scientific, cat# PA5-78996; diluted 1:100) and Rabbit anti-CD163 for M2
macrophages (abcam, cat# ab213612; diluted 1:100). Sections were counterstained with methyl
green. Images were digitally captured with an Olympus BX41 microscope equipped with a
MicroPublisher 5.0 RTV CCD color camera (QImaging).

Measurement of circulating cytokines and CRP in the plasma of LDLR-/- mice
Plasma was collected from whole blood via cardiac puncture at the time of sacrifice using
EDTA as an anti-coagulant. Cytokines were measured in the pooled plasma samples, at every
given week point, with Bio-plex mouse cytokine group I 8-plex assay kit (Lot # 64140214).
Cytokine measured were IL-1b, IL-6, TNF-a, IL-4, IL-10, IL-12, and IFN-g. Manufacturer’s
instructions were followed. Mutant CRP levels were measured by ELISA in the plasma samples
of five out of twelve randomly selected mice at every given week point. Briefly, microtiter wells
were coated with anti-CRP IgG (diluted 1:1000 in 1X TBS) and incubated overnight at 40 C.
Wells were blocked with TBS containing 0.5% gelatin for 45 minutes followed by addition of
pooled plasma samples, diluted in buffer containing 1X TBS, 0.1% gelatin, 0.02% Tween 20
(ELISA buffer, pH 7.2). Wells were incubated with plasma samples for 2 h at 37 °C. After the
CRP incubation step, the wells were washed with ELISA buffer and rabbit anti-CRP antibody
(Sigma, diluted 1/1000 in ELISA buffer), was used (100 μl/well, 1 h at 37 °C) to detect bound
CRP. HRP-conjugated donkey anti-rabbit IgG (GE Healthcare), diluted in ELISA buffer, was
used (100 μl/well, 1 h at 37 °C) as the secondary antibody. Color was developed using ABTS as
the substrate, and the absorbance was read at 405 nm in a microtiter plate reader (Molecular
Devices).
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Data Analysis
For atherosclerotic lesion measurement in the whole aorta and aortic root, median total
lesion was reported and medians were compared. Data was analyzed using non-parametric test
(Mann-Whitney test) using Graphpad Prism software. p < 0.05 was considered statistically
significant. For analysis of circulating cytokines and CRP in the plasma, data is represented as
mean + standard deviation and unpaired student t-test was used to analyze statistically significant
differences. p < 0.05 was considered statistically significant.

Results
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F66A/T76Y/E81A mutant CRP significantly decreased atherosclerotic lesion in the aortae
(en face) of LDLR-/- mice
To investigate the effect of mutant CRP on the early stages of development of
atherosclerosis in LDLR-/- mice, en face atherosclerotic lesion area was analyzed. The
experiment was performed twice with n=6 mice in each group at every given data collection time
point. The data are presented as a combination of two independently performed experiments.
Administration of mutant CRP had no effect on the en face atherosclerotic lesion at 1, 3, and 5
weeks but, at 7th and 9th week (7 weeks: 8 weeks on high fat diet and 7 weeks of mutant CRP
injections, 9 weeks: 10 weeks on high fat diet and 9 weeks of mutant CRP injections), the size of
atherosclerotic lesion area in mutant CRP treated mice was significantly lower when compared
to the lesion area in untreated mice (Fig A.1). In comparison to the untreated mice, the lesion
area was 39% less in mutant CRP treated mice at 7th week (p = 0.007) and 42% less in mutant
CRP treated mice at 9th week (p = 0.002). Also, in untreated group the disease progressed in an
incremental manner from week 1 through week 7 and stayed constant until week 9 but similar
disease progression was not observed in mutant CRP treated group where the disease progressed
from week 1 through week 5 and stayed almost constant until week 9. This data suggest that
mutant CRP decreased the atherosclerotic lesion area in the aortae of LDLR-/- mice between 8
and 10 weeks of high fat diet and 7 and 9 weeks of mutant CRP administration and prevented the
progression of atherosclerosis after 6 weeks of high fat diet and 5 weeks of mutant CRP
administration.
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Figure A.1: F66A/T76Y/E81A mutant CRP reduces atherosclerosis in the whole aorta of
LDLR−/−mice. Quantification of total atherosclerotic plaque or lesion coverage in en
face aorta specimens from untreated and mutant CRP treated LDLR−/− mice maintained
on a high fat diet is shown. The scatterplot represents the quantification of total
atherosclerotic lesion coverage in en face aorta specimens from untreated and mutant
CRP treated LDLR−/− mice. Data were collected at 5 different time points, i.e, 1, 3, 5, 7,
and 9 weeks of mutant CRP administration at alternate days (TBS was injected for
untreated group). A scatterplot of total atherosclerotic lesion coverage is shown. Each
symbol represents the total area of the whole aorta that stained positively for Sudan IV in
individual untreated (blue) or mutant CRP treated (green) LDLR−/− mice. Horizontal
black lines indicate median total lesion area in the whole aorta for each group of animals.
Asterisks (red) denote statistically significant differences between groups (*p < 0.05).
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Statistically significant differences in total lesion coverage is determined by Mann
Whitney test.

The aortic root atherosclerotic lesion area of LDLR-/- mice was unaffected by
F66A/T76Y/E81A mutant CRP.
Another parameter to investigate effect of mutant CRP on the early stages of
atherosclerosis development in LDLR-/- mice was cross-sectional analysis of ORO stained aortic
root sections. The experiment was performed twice with n=6 mice in each group at every given
week time point. The data are presented as a combination of two independently performed
experiments. Mutant CRP did not affect the atherosclerotic lesion area in the aortic root at any
given time point specifically. It neither decreased the lesion area nor delayed the progression of
the disease, as observed in the first set of experiment (Fig A.2). Hence data suggests that mutant
CRP had no effect on the atherosclerotic lesion area in the aortic root of LDLR-/- mice.
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Figure A.2: F66A/T76Y/E81A mutant CRP did not affect the lesion progression in the
aortic root of LDLR−/−mice. Quantification of total lesion area in 8 µm thick aortic root
sections covering the length of the aortic root (from the beginning of the appearance of
aortic valves until the disappearance of valves) from untreated and mutant CRP treated
LDLR−/− mice maintained on a high fat diet is shown. Data was collected at 5 different
time points, i.e, 1, 3, 5, 7, and 9 weeks of mutant CRP administration at alternate days
(TBS was injected for untreated group). A scatterplot of total atherosclerotic lesion
coverage in the aortic root is shown. Each symbol represents the total area of the aortic
root that stained positively for ORO in individual untreated (blue) or mutant CRP treated
(green) LDLR−/− mice. Horizontal black lines indicate the median of total aortic root
lesion area for each group of animals.

The levels of circulatory cytokines were sparsely detectable in the plasma of LDLR-/- mice
In order to analyze the effect of mutant CRP administration in systemic circulation,
circulating levels of pro-inflammatory and anti-inflammatory cytokines were measured in both
untreated and mutant CRP-treated mice (Table A.1). Unfortunately, the cytokines were either
sparsely detectable or not detectable at all. Anti-inflammatory cytokines IL-4 and IL-10 were
undetectable while pro-inflammatory cytokines IL-6, IL-1a, and TNF-a were sparsely
detectable. Therefore, the effect of mutant CRP on the cytokine profiling in the plasma of LDLR/-

mice, could not be evaluated.
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Week of
sacrifice

IL-6 (ng/ml)
Untreated

IL-1β (ng/ml)

CRP- treated

Untreated

TNF-α (ng/ml)

CRP-treated

Untreated

CRP-treated

1

2.41 ± 1.92

2.49 ± 0.73

9.48 ± 10.9

4.33 ± 6.12

118.19 + 90.07

41.49 + 1.93

3

1.39 ± 0.73

2.57 ± 0.27

1.72 ± 0.69

0.99 ± 1.33

26.32 + 1.93

25.2 + 0.33

5

1.22 ± 0.28

1.92 ± 0.96

ND

ND

21.36 + 1.28

91.3 + 7.23

7

2.11 ± 0.24

2.5 ± 1.15

ND

ND

31.34 + 1.29

33.73 + 18.83

9

2.12 ± 1.55

1.32 ± 0.33

0.84 ± 0.91

0.86 ± 0.18

40.48 + 13.08

9.34 + 6.8

Table A.1: Levels of circulating pro-inflammatory cytokines were analyzed in pooled
plasma samples from experiment 1 and experiment 2 respectively and results are
expressed as mean + SE. Samples were collected at five different time points, i.e, 1, 3, 5,
7, and 9 weeks of mutant CRP administration at alternate days (TBS was injected for
control group). No statistically significant differences were found between the untreated
and mutant CRP treated groups at any time point (ND: not detectable).

Mutant CRP levels in the plasma of LDLR-/- mice
To further evaluate the presence of administered mutant CRP in the plasma of LDLR-/mice, CRP ELISA was performed. CRP levels observed in untreated mice are considered
baseline levels, as these mice did not receive mutant CRP. Amongst all week points, mutant CRP
was detected only after 1st week of mutant CRP administration (Table A.2). This could be
explained in light of the half-life of this mutant CRP. Because mutant CRP was injected every 48
hours and the half-life of this CRP is approximately 15-20 hours, there is a possibility that the
mutant CRP was cleared from the system by the time plasma was collected. The detection of
mutant CRP at certain time points above baseline levels can also be explained in part of the
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sample collection time since, we injected mutant CRP every 48 hours and the sample collection
time varied between 24 hours post mutant CRP administration and 48 hours post mutant CRP
administration. Also, no CRP antibodies were detected in the mouse plasma samples (data not
shown).

Week of
sacrifice

CRP concentration (ng/ml)
Untreated

CRP- treated

1

19.4 ± 2.61

341.6 ± 220.7

3

25.8 ± 5.81

27.6 ± 11.89

5

54.4 ± 17.01

78 ± 38.9

7

64.6 ± 47.34

171.8 ± 105.1

9

87 ± 31.32

79 ± 17.73

Table A.2: Circulating levels of mutant CRP were analyzed in pooled plasma samples
from experiment 1 and experiment 2 respectively and results are expressed as mean + SE.
Samples were collected at five different time points, i.e, 1, 3, 5, 7, and 9, weeks of mutant
CRP administration at alternate days (TBS was injected for control group.

Mutant CRP did not alter the MΦ1/ MΦ2 macrophage ratio at the atherosclerotic lesion
area of LDLR-/- mice
To evaluate the effect of mutant CRP on the inflammatory environment, immunostaining
for pro-inflammatory macrophage (MΦ1) and anti-inflammatory macrophage (MΦ2), in the
aortic root atherosclerotic lesions of both untreated and mutant CRP treated mice was performed
using CD 68 as the pan macrophage marker and CD 163 as the MΦ2 macrophage marker. As
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expected, atherosclerotic lesions stained CD 68-positive for macrophages whereas, the lesion
area stained CD 163-negative suggesting that there were no anti-inflammatory MΦ2
macrophages present (Fig A.3A, A.3B). This implies that the macrophages present at the
atherosclerotic lesions were pro-inflammatory MΦ1 macrophages and these data were consistent
for both untreated and mutant CRP treated lesions that further suggests that mutant CRP
administration did affect the macrophage phenotype at the aortic root atherosclerotic lesion area.

A

B

C

CRP

-

+

Figure A.3: Macrophage and CRP immunostaining in aortic root lesions. Representative
aortic root sections from untreated and mutant CRP treated LDLR−/− mice fed on a high
fat diet, stained for pan macrophages using CD 68 as the pan macrophage marker, is
shown (A). CD 68-positive areas are stained brown. For MΦ2 (anti-inflammatory
macrophages) staining, CD 163 was used as a marker (B). Positive CRP stained lesion
areas are indicated in brown (C).
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Mutant CRP was not present at the atherosclerotic lesion in the aortic root area
In order to test the presence of administered mutant CRP at the atherosclerotic lesion in
the aortic root area, CRP immunostaining was performed in the aortic root lesions of both
untreated and mutant CRP treated mice at every given data collection week point. Anti-CRP
gave false-positive staining in the aortic root atherosclerotic lesion of untreated and mutant CRP
treated mice (Fig A.3C). This suggests that anti-CRP (both polyclonal anti-CRP and (Fab)fragmented anti-CRP) was cross reacting with immune complexes present in the atherosclerotic
lesion such as ox-LDL-IgG immune complexes. Due to the false-positive CRP staining, the
presence and absence of mutant CRP at the aortic root atherosclerotic lesion could not be
evaluated.
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Discussion
In this study we investigated the effect of a non-native pentameric CRP created by sitedirected mutagenesis, F66A/T76Y/E81A mutant CRP, that does not bind to PCh since the PCh
binding site of this mutant CRP is abolished due to mutations of critical amino acids forming the
PCh-binding pocket, i.e, Glu81, Phe66 and Thr76, on the development of atherosclerosis
employing LDL receptor knockout mouse model of atherosclerosis. Our major findings were as
follows: 1) F66A/T76Y/E81A mutant CRP, in the whole aorta, had an effect on the progression
and development of atherosclerosis wherein administration of this protein significantly reduced
the size of en face atherosclerotic lesion in LDLR-/- mice at 8-10 weeks of high fat diet and
halted the progression of the disease post 6 weeks of high fat diet. 3) Mutant CRP showed no
effect on the progression and development of atherosclerosis in the aortic root. 4) The effect of
mutant CRP administration on the levels of circulating cytokines in the plasma could not be
evaluated. 5) Mutant CRP administration did not alter the macrophage phenotype at the
atherosclerotic lesion area. 6) The presence of administered mutant CRP could not be evaluated
at the atherosclerotic lesion area in the aortic root.
In the current study, we could not analyze the presence of administered
F66A/T76Y/E81A mutant CRP at atherosclerotic lesion in the aortic root because anti-CRP
(both polyclonal anti-CRP and (Fab)-fragmented anti-CRP) provided false-positive staining as
mutant CRP was detected in the aortic root atherosclerotic lesion of both untreated and mutant
CRP treated mice. Since, the lesion area in the aortic root is extremely complex, one of the
possible reasons can be that anti-CRP was recognizing and cross reacting with immune
complexes present in the atherosclerotic lesion such as ox-LDL-IgG immune complexes (1-2).
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Macrophages are heterogeneous cell populations that have been shown to be present in
the developing lesion during pathogenesis of atherosclerosis. Macrophages have the ability to
switch from their “classically activated” pro-inflammatory (MΦ1) phenotype to an “alternative”
anti-inflammatory (MΦ2) phenotype and vice versa, depending on the microenvironment or
specific signals sensed by them (3-4). In order to further understand the atheroprotective effect of
F66A/T76Y/E81A mutant CRP in lieu of its ability to alter the macrophage phenotype from antiinflammatory (MΦ2) to pro-inflammatory (MΦ1), we stained the aortic root atherosclerotic
lesion for macrophages. The lesion areas were found to be macrophage-rich as they identified as
CD68-positive while, in contrast, the lesion area stained negative for MΦ2 phenotype in both
untreated and mutant CRP treated mice suggesting that the atherosclerotic lesion had a greater
concentration of macrophages specifically M1 macrophages and F66A/T76Y/E81A mutant CRP
did not affect or alter macrophage phenotype.
Since, atherosclerosis is considered as a chronic inflammatory condition with
concomitant increase in pro-inflammatory cytokines such as IL-6, IL-1b, TNF-a and also, it has
been shown that native CRP can interact with modified LDL and reduce the proinflammatory
effects produced by modified LDL and foam cells. Therefore, in order to observe the effect of
F66A/T76Y/E81A mutant CRP on the levels of circulating cytokines in the plasma, a Bio-plex
multi cytokine assay was performed. Unfortunately, the cytokines could not be detected as they
were either sparsely detectable or not detectable at all. Anti-inflammatory cytokines IL-4 and IL10 were undetectable while pro-inflammatory cytokines IL-6, IL-1a, and TNF-a were sparsely
detectable and hence, the effect of mutant CRP on the cytokine profiling in the plasma of LDLR/-

mice could not be evaluated. Along with it, there were no antibodies produced against

administered mutant CRP.
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